[{"title01":"Molecular profiling of EBV associated diffuse large B-cell lymphoma","title02":"Molecular profiling of EBV associated diffuse large B-cell lymphoma","journal":"Leukemia","issue":"Leukemia. 2023 Jan 5. doi: 10.1038\/s41375-022-01804-w. Online ahead of print.","author":"Frontzek F, Staiger AM, Wullenkord R, Grau M, Zapukhlyak M, Kurz KS, Horn H, Erdmann T, Fend F, Richter J, Klapper W, Lenz P, Hailfinger S, Tasidou A, Trautmann M, Hartmann W, Rosenwald A, Quintanilla-Martinez L, Ott G, Anagnostopoulos I, Lenz G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36604606"},{"title01":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","title02":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","journal":"Leukemia","issue":"Leukemia. 2023 Jan 3. doi: 10.1038\/s41375-022-01803-x. Online ahead of print.","author":"Jim\u00e9nez-Ubieto A, Poza M, Martin-Mu\u00f1oz A, Ruiz-Heredia Y, Dorado S, Figaredo G, Rosa-Rosa JM, Rodriguez A, Barcena C, Navamuel LP, Carrillo J, Sanchez R, Rufian L, Ju\u00e1rez A, Rodriguez M, Wang C, de Toledo P, Grande C, Mollejo M, Casado LF, Calbacho M, Baumann T, Rapado I, Gallardo M, Sarandeses P, Ayala R, Mart\u00ednez-L\u00f3pez J, Barrio S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36596983"},{"title01":"JCO Flashback: Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998)","title02":"JCO Flashback:<\/i> Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998)","journal":"J Clin Oncol","issue":"2023 Jan 10;41(2):153.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36603539"},{"title01":"Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program","title02":"Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program","journal":"J Clin Oncol","issue":"2023 Jan 10;41(2):154-162.","author":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36603541"},{"title01":"Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma","title02":"Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2023 Jan 12. doi: 10.3324\/haematol.2022.282265. Online ahead of print.","author":"Song JY, Nwangwu M, He TF, Zhang W, Meawad H, Bedell V, Murata-Collins J, Skrabek P, Nasr MR, Scott D, Godfrey J, Lee P, Chan WC, Weisenburger DD, Perry AM, Herrera AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36632739"},{"title01":"Pseudo-faggot cells in splenic marginal zone lymphoma","title02":"Pseudo-faggot cells in splenic marginal zone lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jan 6. doi: 10.1111\/bjh.18621. Online ahead of print.","author":"Wilson J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36606572"},{"title01":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","title02":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jan 10. doi: 10.1111\/bjh.18640. Online ahead of print.","author":"Puckrin R, Chua N, Chin K, Peters A, Duggan P, Shafey M, Storek J, Jamani K, Owen C, Stewart D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36625160"},{"title01":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial","title02":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial","journal":"Blood","issue":"Blood. 2023 Jan 10:blood.2022017734. doi: 10.1182\/blood.2022017734. Online ahead of print.","author":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, Kim WSS, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36626583"},{"title01":"Lymphoplasmacytic lymphoma with IgG paraprotein and extensive plasmacytic differentiation mimicking plasma cell neoplasm","title02":"Lymphoplasmacytic lymphoma with IgG paraprotein and extensive plasmacytic differentiation mimicking plasma cell neoplasm","journal":"Blood","issue":"2022 Dec 29;140(26):2857.","author":"Qiu L, Quesada AE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36580339"},{"title01":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","title02":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jan 9:JCO2201365. doi: 10.1200\/JCO.22.01365. Online ahead of print.","author":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36623248"},{"title01":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","title02":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jan 4:JCO2200940. doi: 10.1200\/JCO.22.00940. Online ahead of print.","author":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36599114"},{"title01":"Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective observational study","title02":"Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective observational study","journal":"Haematologica","issue":"Haematologica. 2023 Jan 5. doi: 10.3324\/haematol.2022.282269. Online ahead of print.","author":"Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36601982"},{"title01":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","title02":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jan 5. doi: 10.1111\/bjh.18630. Online ahead of print.","author":"Dima D, Li A, Granat LM, Dhillon P, Chamseddine F, Yalamanchali A, Mirzai S, Wei W, Samaras CJ, Valent J, Anwer F, Khouri J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36604838"},{"title01":"High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma","title02":"High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma","journal":"Blood","issue":"Blood. 2023 Jan 5:blood.2022017094. doi: 10.1182\/blood.2022017094. Online ahead of print.","author":"Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat RE, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36603186"},{"title01":"A phase II clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma","title02":"A phase II clinical trial of combined BRAF\/MEK<\/i> inhibition for BRAFV600E-mutated multiple myeloma","journal":"Blood","issue":"Blood. 2023 Jan 6:blood.2022017789. doi: 10.1182\/blood.2022017789. Online ahead of print.","author":"Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kort\u00fcm KM, M\u00fcller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel KC, Raab MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36608320"},{"title01":"Ubiquitin receptor PSMD4\/Rpn10 is a novel therapeutic target in multiple myeloma","title02":"Ubiquitin receptor PSMD4\/Rpn10 is a novel therapeutic target in multiple myeloma","journal":"Blood","issue":"Blood. 2023 Jan 11:blood.2022017897. doi: 10.1182\/blood.2022017897. Online ahead of print.","author":"Du T, Song Y, Ray A, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC, Wan X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36630605"},{"title01":"Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants","title02":"Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants","journal":"N Engl J Med","issue":"N Engl J Med. 2023 Jan 11. doi: 10.1056\/NEJMc2210825. Online ahead of print.","author":"Schuster JE, Hamdan L, Dulek DE, Kitko CL, Batarseh E, Haddadin Z, Stewart LS, Stahl A, Potter M, Rahman H, Kalams SA, Coffin S, Ardura MI, Wattier RL, Maron G, Bocchini CE, Moulton EA, Grimley M, Paulsen G, Harrison CJ, Freedman J, Carpenter PA, Englund JA, Munoz FM, Danziger-Isakov L, Spieker AJ, Halasa N; Pediatric HCT Flu Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36630610"},{"title01":"Focusing on the eye signs of Alport syndrome in a 40-year-old man who previously had a kidney transplant and hearing loss","title02":"Focusing on the eye signs of Alport syndrome in a 40-year-old man who previously had a kidney transplant and hearing loss","journal":"Lancet","issue":"2023 Jan 7;401(10370):e1.","author":"Kovalchuk B, Khoramnia R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36610770"},{"title01":"Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study","title02":"Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jan 6:JCO2200509. doi: 10.1200\/JCO.22.00509. Online ahead of print.","author":"Miklos DB, Abu Zaid M, Cooney JP, Albring JC, Flowers M, Skarbnik AP, Yakoub-Agha I, Ko BS, Bruno B, Waller EK, Yared J, Sohn SK, Bulabois CE, Teshima T, Jacobsohn D, Greinix H, Mokatrin A, Lee Y, Wahlstrom JT, Styles L, Socie G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36608310"},{"title01":"Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease","title02":"Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jan 9:JCO2201203. doi: 10.1200\/JCO.22.01203. Online ahead of print.","author":"Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36623245"},{"title01":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","title02":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jan 10. doi: 10.1111\/bjh.18640. Online ahead of print.","author":"Puckrin R, Chua N, Chin K, Peters A, Duggan P, Shafey M, Storek J, Jamani K, Owen C, Stewart D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36625160"},{"title01":"Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants","title02":"Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants","journal":"N Engl J Med","issue":"N Engl J Med. 2023 Jan 11. doi: 10.1056\/NEJMc2210825. Online ahead of print.","author":"Schuster JE, Hamdan L, Dulek DE, Kitko CL, Batarseh E, Haddadin Z, Stewart LS, Stahl A, Potter M, Rahman H, Kalams SA, Coffin S, Ardura MI, Wattier RL, Maron G, Bocchini CE, Moulton EA, Grimley M, Paulsen G, Harrison CJ, Freedman J, Carpenter PA, Englund JA, Munoz FM, Danziger-Isakov L, Spieker AJ, Halasa N; Pediatric HCT Flu Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36630610"},{"title01":"Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease","title02":"Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jan 9:JCO2201203. doi: 10.1200\/JCO.22.01203. Online ahead of print.","author":"Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36623245"},{"title01":"E3-ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia","title02":"E3-ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jan 12. doi: 10.3324\/haematol.2022.281955. Online ahead of print.","author":"Zhang K, Liu D, Li Y, Shi Z, Guo J, Gao C, Wang H, Ju Z, Diao D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36632737"},{"title01":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","title02":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jan 10. doi: 10.1111\/bjh.18640. Online ahead of print.","author":"Puckrin R, Chua N, Chin K, Peters A, Duggan P, Shafey M, Storek J, Jamani K, Owen C, Stewart D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36625160"},{"title01":"MYB insufficiency disrupts proteostasis in hematopoietic stem cells leading to age-related neoplasia","title02":"MYB insufficiency disrupts proteostasis in hematopoietic stem cells leading to age-related neoplasia","journal":"Blood","issue":"Blood. 2023 Jan 5:blood.2022019138. doi: 10.1182\/blood.2022019138. Online ahead of print.","author":"Clarke ML, Lemma RB, Walton DS, Volpe G, Noyvert B, Gabrielsen OS, Frampton J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36603185"},{"title01":"What to expect when an ITP patient is expecting","title02":"What to expect when an ITP patient is expecting","journal":"Blood","issue":"2023 Jan 5;141(1):3-4.","author":"Perez Botero J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36602822"},{"title01":"Balancing the Qi in ITP","title02":"Balancing the Qi in ITP","journal":"Blood","issue":"2022 Dec 29;140(26):2768-2770.","author":"Zehnder JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36580341"},{"title01":"The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes","title02":"The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes","journal":"Leukemia","issue":"Leukemia. 2023 Jan 12. doi: 10.1038\/s41375-023-01810-6. Online ahead of print.","author":"Trempenau ML, Schuster MB, Pundhir S, Pereira MA, Kalvisa A, Tapia M, Su J, Ge Y, de Boer B, Balhuizen A, Bagger FO, Shliaha P, Sroczynska P, Walfridsson J, Gr\u00f8nb\u00e6k K, Theilgaard-M\u00f6nch K, Jensen ON, Helin K, Porse BT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36631623"},{"title01":"High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia","title02":"High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Dec 30. doi: 10.1038\/s41375-022-01800-0. Online ahead of print.","author":"Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, Fagnan A, Thirant C, Federici L, Touchard L, Lecluse Y, Jetten A, Geoerger B, Lapillonne H, Solary E, Gaudry M, Meshinchi S, Pflumio F, Auberger P, Lobry C, Petit A, Jacquel A, Mercher T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36585521"},{"title01":"Conditioning Regimen in Patients With Adult Acute B Lymphoblastic Leukemia","title02":"Conditioning Regimen in Patients With Adult Acute B Lymphoblastic Leukemia","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jan 3:JCO2202230. doi: 10.1200\/JCO.22.02230. Online ahead of print.","author":"Shibusawa M, Tanimoto T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36595732"},{"title01":"TAL1 activation in T-Cell acute lymphoblastic leukemia: A novel oncogenic 3′ neoenhancer","title02":"TAL1 activation in T-Cell acute lymphoblastic leukemia: A novel oncogenic 3′ neoenhancer","journal":"Haematologica","issue":"Haematologica. 2023 Jan 12. doi: 10.3324\/haematol.2022.281583. Online ahead of print.","author":"Smith C, Goyal A, Weichenhan D, Allemand E, Mayakonda A, Toprak U, Riedel A, Balducci E, Manojkumar M, Pejkovska A, M\u00fccke O, Sollier E, Bakr A, Breuer K, Lutsik P, Hermine O, Spicuglia S, Asnafi V, Plass C, Touzart A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36632736"},{"title01":"E3-ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia","title02":"E3-ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jan 12. doi: 10.3324\/haematol.2022.281955. Online ahead of print.","author":"Zhang K, Liu D, Li Y, Shi Z, Guo J, Gao C, Wang H, Ju Z, Diao D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36632737"},{"title01":"High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 – ‘Veritas’ study","title02":"High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 – ‘Veritas’ study","journal":"Haematologica","issue":"Haematologica. 2023 Jan 12. doi: 10.3324\/haematol.2022.282116. Online ahead of print.","author":"Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarf\u00f2 L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Fo\u00e0 R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36632738"},{"title01":"Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2×2 phase II trial (DECIDER)","title02":"Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2×2 phase II trial (DECIDER)","journal":"Haematologica","issue":"Haematologica. 2023 Jan 5. doi: 10.3324\/haematol.2022.282258. Online ahead of print.","author":"Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, G\u00f6tze KS, Schlenk RF, D\u00f6hner K, Salih HR, Heil G, M\u00fcller-Tidow C, Brugger W, K\u00fcndgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, W\u00e4sch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, D\u00f6hner H, L\u00fcbbert M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36601981"},{"title01":"Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement","title02":"Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4<\/i> rearrangement","journal":"Blood","issue":"2023 Jan 5;141(1):121.","author":"Heuchon M, Wiber M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36602820"},{"title01":"Treatment intensity in AML: a double-edged sword","title02":"Treatment intensity in AML: a double-edged sword","journal":"Blood","issue":"2023 Jan 5;141(1):5-7.","author":"Friend BD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36602824"},{"title01":"Central Nervous System Status is Prognostic in T-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report","title02":"Central Nervous System Status is Prognostic in T-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report","journal":"Blood","issue":"Blood. 2023 Jan 5:blood.2022018653. doi: 10.1182\/blood.2022018653. Online ahead of print.","author":"Gossai N, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, Loh ML, Raetz EA, Winick NJ, Burke MJ, Carroll AJ, Esiashvili N, Heerema NA, Carroll WL, Hunger SP, Dunsmore KP, Winter SS, Teachey DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36603187"},{"title01":"Restoring NK cell functions in AML relapse","title02":"Restoring NK cell functions in AML relapse","journal":"Blood","issue":"2022 Dec 29;140(26):2765-2766.","author":"Kim S, Choi J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36580344"},{"title01":"DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage","title02":"DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage","journal":"Blood","issue":"Blood. 2022 Dec 29:blood.2022018428. doi: 10.1182\/blood.2022018428. Online ahead of print.","author":"Vekariya U, Toma MM, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik MA, Sykes S, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta E, Levine RL, Tallman MS, Fernandez H, Litzow MR, Gupta G, Masson JY, Skorski T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36580665"},{"title01":"INPP5K controls the dynamic structure and signaling of wild type and mutated, leukemia-associated IL7 receptors","title02":"INPP5K controls the dynamic structure and signaling of wild type and mutated, leukemia-associated IL7 receptors","journal":"Blood","issue":"Blood. 2023 Jan 4:blood.2022017819. doi: 10.1182\/blood.2022017819. Online ahead of print.","author":"Mo\u00ebs B, Li H, Molina-Ortiz P, Radermecker C, Rosu A, Vande Catsyne CA, Sayyed SA, Fontela J, Duque M, Mostafa A, Azzi A, Barata JT, Merino R, Xu C, Desmet CJ, Schurmans S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36599086"},{"title01":"Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany","title02":"Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 27. doi: 10.1111\/bjh.18610. Online ahead of print.","author":"Frietsch JJ, Flossdorf S, Beck JF, Kr\u00f6ger N, Fleischhauer K, Dreger P, Schetelig J, Bornh\u00e4user M, Hochhaus A, Hilgendorf I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36573337"},{"title01":"Believe in haploidentical HSCT: less is better","title02":"Believe in haploidentical HSCT: less is better","journal":"Blood","issue":"2022 Dec 15;140(24):2523-2524.","author":"Bertaina A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36520474"},{"title01":"The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex- mediated quiescence","title02":"The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex- mediated quiescence","journal":"Blood","issue":"Blood. 2022 Dec 21:blood.2022016929. doi: 10.1182\/blood.2022016929. Online ahead of print.","author":"Greenberg ZJ, Monlish D, Chiquetto Paracatu L, Dong Q, Rettig MP, Roundy ND, Gaballa R, Li W, Yang W, Luke CJ, Schuettpelz L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36542833"},{"title01":"Oxygen Delivery in the Treatment of Anemia","title02":"Oxygen Delivery in the Treatment of Anemia","journal":"N Engl J Med","issue":"2022 Dec 22;387(25):2362-2365.","author":"Bunn HF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546628"},{"title01":"Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32\u2009Years of passive surveillance data","title02":"Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32\u2009Years of passive surveillance data","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 23. doi: 10.1111\/bjh.18627. Online ahead of print.","author":"Jacobs JW, Booth GS, Guarente J, Schlafer D, Zheng L, Adkins BD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564040"},{"title01":"Phenotypes of adults with Fanconi anaemia","title02":"Phenotypes of adults with Fanconi anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 13. doi: 10.1111\/bjh.18603. Online ahead of print.","author":"Wang YM, Loveless M, Miller E, Nelson AS, Mehta PA, Davies SM, Myers KC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36513378"},{"title01":"Clinical severity and blood rheology in patients with sickle cell anaemia and co-existing autoimmune disease","title02":"Clinical severity and blood rheology in patients with sickle cell anaemia and co-existing autoimmune disease","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 22. doi: 10.1111\/bjh.18624. Online ahead of print.","author":"Poutrel S, Boisson C, Nader E, Renoux C, Virot E, Catella J, Marie M, Hot A, Cannas G, Bertrand Y, Joly P, Connes C, Merazga S, Gauthier A, Connes P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36545779"},{"title01":"Non-steroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal Hematodiaphyseal Dysplasia","title02":"Non-steroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal Hematodiaphyseal Dysplasia","journal":"Blood","issue":"Blood. 2022 Dec 27:blood.2022018667. doi: 10.1182\/blood.2022018667. Online ahead of print.","author":"Brown TJ, Barrett NA, Meng H, Ricciotti E, McDonnell CM, Dancis A, Qualtieri JN, FitzGerald GA, Cotter M, Babushok DV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36574346"},{"title01":"Differential diagnosis of bone marrow failure syndromes guided by machine learning","title02":"Differential diagnosis of bone marrow failure syndromes guided by machine learning","journal":"Blood","issue":"Blood. 2022 Dec 21:blood.2022017518. doi: 10.1182\/blood.2022017518. Online ahead of print.","author":"Gutierrez-Rodrigues F, Munger E, Ma X, Groarke EM, Tang Y, Patel BA, Catto LFB, Cl\u00e9 DV, Niewisch MR, Paiva RM, Donaires F, Pinto AL, Borges G, Santana BA, McReynolds LJ, Giri N, Altintas B, Fan X, Shalhoub RN, Siwy CM, Diamond C, Quinones Raffo D, Craft KM, Kajigaya S, Summers RM, Liu PP, Cunningham L, Hickstein DD, Dunbar CE, Pasquini R, de Oliveira MM, Velloso EDRP, Alter BP, Savage SA, Bonfim CMS, Wu CO, Calado RT, Young NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36542832"},{"title01":"Tacrolimus prevents complement-mediated Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis of mesenchymal stem cells from immune thrombocytopenia","title02":"Tacrolimus prevents complement-mediated Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis of mesenchymal stem cells from immune thrombocytopenia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 22. doi: 10.1111\/bjh.18625. Online ahead of print.","author":"Cai X, Wu J, An ZY, Wang CC, Zhu XL, He Y, Fu HX, Huang XJ, Zhang XH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546515"},{"title01":"Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32\u2009Years of passive surveillance data","title02":"Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32\u2009Years of passive surveillance data","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 23. doi: 10.1111\/bjh.18627. Online ahead of print.","author":"Jacobs JW, Booth GS, Guarente J, Schlafer D, Zheng L, Adkins BD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564040"},{"title01":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study","title02":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study","journal":"Blood","issue":"Blood. 2022 Dec 21:blood.2022018730. doi: 10.1182\/blood.2022018730. Online ahead of print.","author":"Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, Izutsu K, Morschhauser F, Lunning MA, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36542826"},{"title01":"GPRC5D-Targeted CAR T Cells for Myeloma","title02":"GPRC5D-Targeted CAR T Cells for Myeloma","journal":"N Engl J Med","issue":"2022 Dec 15;387(24):2295-2296.","author":"Quint\u00e1s-Cardama A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36516097"},{"title01":"GPRC5D-Targeted CAR T Cells for Myeloma. Reply","title02":"GPRC5D-Targeted CAR T Cells for Myeloma. Reply","journal":"N Engl J Med","issue":"2022 Dec 15;387(24):2296.","author":"Mailankody S, Brentjens RJ, Smith EL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36516098"},{"title01":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","title02":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","journal":"Lancet Oncol","issue":"Lancet Oncol. 2022 Dec 14:S1470-2045(22)00693-3. doi: 10.1016\/S1470-2045(22)00693-3. Online ahead of print.","author":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36528035"},{"title01":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial","title02":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 15:S2352-3026(22)00350-7. doi: 10.1016\/S2352-3026(22)00350-7. Online ahead of print.","author":"Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36529145"},{"title01":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","title02":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 15:S2352-3026(22)00360-X. doi: 10.1016\/S2352-3026(22)00360-X. Online ahead of print.","author":"Beksac M, Hayden P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36529146"},{"title01":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice","title02":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.280482. Online ahead of print.","author":"Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546453"},{"title01":"Maintenance therapy in multiple myeloma: Two is not always better than one","title02":"Maintenance therapy in multiple myeloma: Two is not always better than one","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 21. doi: 10.1111\/bjh.18614. Online ahead of print.","author":"Offidani M, Mor\u00e8 S, Corvatta L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36541138"},{"title01":"The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial","title02":"The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 21. doi: 10.1111\/bjh.18600. Online ahead of print.","author":"Jenner MW, Pawlyn C, Davies FE, Menzies T, Hockaday A, Olivier C, Jones JR, Karunanithi K, Lindsay J, Kishore B, Cook G, Drayson MT, Kaiser MF, Owen RG, Gregory W, Cairns DA, Morgan GJ, Jackson GH; UK National Cancer Research Institute (NCRI) Haemato-oncology Clinical Studies Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36541152"},{"title01":"Optimizing the value of lenalidomide maintenance by genetic profiling – an analysis of 556 Myeloma XI trial patients","title02":"Optimizing the value of lenalidomide maintenance by genetic profiling – an analysis of 556 Myeloma XI trial patients","journal":"Blood","issue":"Blood. 2022 Dec 23:blood.2022018339. doi: 10.1182\/blood.2022018339. Online ahead of print.","author":"Panopoulou A, Cairns DA, Holroyd AE, Nichols I, Cray N, Pawlyn C, Cook G, Drayson MT, Boyd KD, Davies FE, Jenner MW, Morgan GJ, Owen RG, Houlston RS, Jackson GH, Kaiser MF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564045"},{"title01":"Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters","title02":"Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters","journal":"Leukemia","issue":"Leukemia. 2022 Dec 22. doi: 10.1038\/s41375-022-01782-z. Online ahead of print.","author":"Bruch PM, Dietrich S, Finel H, Boumendil A, Greinix H, Heinicke T, Bethge W, Beelen D, Schmid C, Martin H, Castagna L, Scheid C, Sch\u00e4fer-Eckart K, Bittenbring J, Finke J, Sengeloev H, Heiblig M, Cornelissen J, Chevallier P, Mohty M, Robinson S, Montoto S, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36550212"},{"title01":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","title02":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","journal":"Lancet Oncol","issue":"Lancet Oncol. 2022 Dec 14:S1470-2045(22)00693-3. doi: 10.1016\/S1470-2045(22)00693-3. Online ahead of print.","author":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36528035"},{"title01":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial","title02":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 15:S2352-3026(22)00350-7. doi: 10.1016\/S2352-3026(22)00350-7. Online ahead of print.","author":"Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36529145"},{"title01":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","title02":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 15:S2352-3026(22)00360-X. doi: 10.1016\/S2352-3026(22)00360-X. Online ahead of print.","author":"Beksac M, Hayden P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36529146"},{"title01":"A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","title02":"A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Dec 15. doi: 10.3324\/haematol.2022.281471. Online ahead of print.","author":"Hudspeth M, Mori S, Nachbaur D, Perez-Simon JA, St\u00f6lzel F, Riches M, Wu W, Zhang P, Agarwal S, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519326"},{"title01":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","title02":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.281754. Online ahead of print.","author":"Chihara D, Gras L, Zinger N, Kr\u00f6ger N, Mayer J, Passweg J, De Latour RP, Byrne J, Kr\u00fcger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546416"},{"title01":"Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors’ reply","title02":"Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors’ reply","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 23. doi: 10.1111\/bjh.18626. Online ahead of print.","author":"Matsuda K, Konuma T, Yanada M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564809"},{"title01":"Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany","title02":"Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 27. doi: 10.1111\/bjh.18610. Online ahead of print.","author":"Frietsch JJ, Flossdorf S, Beck JF, Kr\u00f6ger N, Fleischhauer K, Dreger P, Schetelig J, Bornh\u00e4user M, Hochhaus A, Hilgendorf I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36573337"},{"title01":"Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML","title02":"Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 21. doi: 10.1111\/bjh.18622. Online ahead of print.","author":"Scaradavou A, Boelens JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36544239"},{"title01":"Chronic GVHD on the move","title02":"Chronic GVHD on the move","journal":"Blood","issue":"2022 Dec 22;140(25):2660-2661.","author":"M\u00fcller AMS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548018"},{"title01":"Oxidative DNA Damage in Reconstituting T-cells is Associated with Relapse and Inferior Survival Following Allo-SCT","title02":"Oxidative DNA Damage in Reconstituting T-cells is Associated with Relapse and Inferior Survival Following Allo-SCT","journal":"Blood","issue":"Blood. 2022 Dec 23:blood.2022017267. doi: 10.1182\/blood.2022017267. Online ahead of print.","author":"Karl F, Liang C, Boettcher-Loschinski R, Stoll A, Flamann CS, Richter S, Lischer C, V\u00f6lkl S, Jacobs B, B\u00f6ttcher M, Jitschin R, Bruns H, Fischer T, Holler E, Roesler W, Dandekar T, Mackensen A, Mougiakakos D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564029"},{"title01":"Prevention of acute GVHD disease using an orthogonal IL-2\/IL-2R\u03b2 system to selectively expand regulatory T-cells in vivo","title02":"Prevention of acute GVHD disease using an orthogonal IL-2\/IL-2R\u03b2 system to selectively expand regulatory T-cells in vivo","journal":"Blood","issue":"Blood. 2022 Dec 23:blood.2022018440. doi: 10.1182\/blood.2022018440. Online ahead of print.","author":"Lopes Ramos T, Bolivar-Wagers S, Jin S, Thangavelu G, Simonetta F, Lin PY, Hirai T, Saha A, Koehn BH, L Su L, Picton LK, Baker J, Lohmeyer JK, Riddle MJ, Eide C, Tolar J, Panoskaltsis-Mortari A, Wagner JE, Garcia KC, Negrin RS, Blazar BR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564052"},{"title01":"The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell-mediated graft-versus-host disease","title02":"The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell-mediated graft-versus-host disease","journal":"Blood","issue":"Blood. 2022 Dec 27:blood.2022017201. doi: 10.1182\/blood.2022017201. Online ahead of print.","author":"Cheng Q, Wang D, Lai X, Liu Y, Zuo Y, Zhang W, Lei L, Chen J, Liu H, Wang Y, Liu H, Zheng H, Wu D, Xu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36574342"},{"title01":"Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD","title02":"Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD","journal":"Blood","issue":"Blood. 2022 Dec 27:blood.2022017982. doi: 10.1182\/blood.2022017982. Online ahead of print.","author":"Lohmeyer JK, Hirai T, Turkoz M, Buhler S, Lopes Ramos T, K\u00f6hler N, Baker J, Melotti A, Wagner I, Pradier A, Wang S, Ji X, Becattini S, Villard J, Merkler D, Chalandon Y, Negrin RS, Simonetta F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36574344"},{"title01":"Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters","title02":"Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters","journal":"Leukemia","issue":"Leukemia. 2022 Dec 22. doi: 10.1038\/s41375-022-01782-z. Online ahead of print.","author":"Bruch PM, Dietrich S, Finel H, Boumendil A, Greinix H, Heinicke T, Bethge W, Beelen D, Schmid C, Martin H, Castagna L, Scheid C, Sch\u00e4fer-Eckart K, Bittenbring J, Finke J, Sengeloev H, Heiblig M, Cornelissen J, Chevallier P, Mohty M, Robinson S, Montoto S, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36550212"},{"title01":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","title02":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","journal":"Leukemia","issue":"Leukemia. 2022 Dec 22. doi: 10.1038\/s41375-022-01798-5. Online ahead of print.","author":"Anderson NR, Sheth V, Li H, Harris MW, Qiu S, Crossman DK, Kumar H, Agarwal P, Nagasawa T, Paterson AJ, Welner RS, Bhatia R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36550214"},{"title01":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","title02":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","journal":"Lancet Oncol","issue":"Lancet Oncol. 2022 Dec 14:S1470-2045(22)00693-3. doi: 10.1016\/S1470-2045(22)00693-3. Online ahead of print.","author":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36528035"},{"title01":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial","title02":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 15:S2352-3026(22)00350-7. doi: 10.1016\/S2352-3026(22)00350-7. Online ahead of print.","author":"Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36529145"},{"title01":"A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","title02":"A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Dec 15. doi: 10.3324\/haematol.2022.281471. Online ahead of print.","author":"Hudspeth M, Mori S, Nachbaur D, Perez-Simon JA, St\u00f6lzel F, Riches M, Wu W, Zhang P, Agarwal S, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519326"},{"title01":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","title02":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.281754. Online ahead of print.","author":"Chihara D, Gras L, Zinger N, Kr\u00f6ger N, Mayer J, Passweg J, De Latour RP, Byrne J, Kr\u00fcger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546416"},{"title01":"Tacrolimus prevents complement-mediated Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis of mesenchymal stem cells from immune thrombocytopenia","title02":"Tacrolimus prevents complement-mediated Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis of mesenchymal stem cells from immune thrombocytopenia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 22. doi: 10.1111\/bjh.18625. Online ahead of print.","author":"Cai X, Wu J, An ZY, Wang CC, Zhu XL, He Y, Fu HX, Huang XJ, Zhang XH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546515"},{"title01":"Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia","title02":"Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia","journal":"Leukemia","issue":"Leukemia. 2022 Dec 20. doi: 10.1038\/s41375-022-01756-1. Online ahead of print.","author":"Ford AM, Colman S, Greaves M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36536099"},{"title01":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","title02":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Dec 21. doi: 10.1038\/s41375-022-01789-6. Online ahead of print.","author":"Li K, Du Y, Cai Y, Liu W, Lv Y, Huang B, Zhang L, Wang Z, Liu P, Sun Q, Li N, Zhu M, Bosco B, Li L, Wu W, Wu L, Li J, Wang Q, Hong M, Qian S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36543880"},{"title01":"A novel Colony Stimulating Factor 3 Receptor activating mutation identified in a patient with chronic neutrophilic leukemia","title02":"A novel Colony Stimulating Factor 3 Receptor activating mutation identified in a patient with chronic neutrophilic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Dec 29. doi: 10.3324\/haematol.2022.281828. Online ahead of print.","author":"Maniaci BN, Chung J, Sanz-Altamira P, DeAngelo DJ, Maxson JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36579444"},{"title01":"CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine","title02":"CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine","journal":"Haematologica","issue":"Haematologica. 2022 Dec 15. doi: 10.3324\/haematol.2022.281444. Online ahead of print.","author":"Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519323"},{"title01":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","title02":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Dec 15. doi: 10.3324\/haematol.2022.281692. Online ahead of print.","author":"Kuusanm\u00e4ki H, Kyt\u00f6l\u00e4 S, V\u00e4nttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, R\u00e4ty R, It\u00e4l\u00e4-Remes M, V\u00e4strik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Py\u00f6r\u00e4l\u00e4 M, Rimpil\u00e4inen J, Siitonen T, Kontro M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519325"},{"title01":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","title02":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.281754. Online ahead of print.","author":"Chihara D, Gras L, Zinger N, Kr\u00f6ger N, Mayer J, Passweg J, De Latour RP, Byrne J, Kr\u00fcger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546416"},{"title01":"Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)","title02":"Retrospective analysis of a cohort of 41 de novo<\/i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.282162. Online ahead of print.","author":"Algrin C, P\u00e9rol L, Chapiro E, Baseggio L, Maloum K, Settegrana C, Lesesve JF, Siavellis J, Delmer A, Michallet AS, Ferrant E, Feugier P, Tomowiak C, Brion A, Ghez D, Fornecker LM, Ivanoff S, Struski S, Sutton L, Radford-Weiss I, Eclache V, Lefebvre C, Leblond V, Nguyen-Khac F, Roos-Weil D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546425"},{"title01":"Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study","title02":"Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.282268. Online ahead of print.","author":"Benintende G, Innocenti I, Fresa A, Autore F, Tomasso A, Piciocchi A, Vuono F, Stirparo L, Mosca A, Bacigalupo A, Gattei V, Efremov D, Sangiorgi E, Laurenti L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546426"},{"title01":"Radical surgery and venetoclax + azacitidine in an octogenarian with acute myeloid leukemia","title02":"Radical surgery and venetoclax + azacitidine in an octogenarian with acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.282282. Online ahead of print.","author":"Ramdohr F, Hennings R, Monecke A, Kayser S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546450"},{"title01":"Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia","title02":"Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 22. doi: 10.1111\/bjh.18608. Online ahead of print.","author":"Salomao N, Maslah N, Giulianelli A, Drevon L, Aguinaga L, Gu X, Cassinat B, Giraudier S, Fenaux P, Fahraeus R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546586"},{"title01":"Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors’ reply","title02":"Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors’ reply","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 23. doi: 10.1111\/bjh.18626. Online ahead of print.","author":"Matsuda K, Konuma T, Yanada M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564809"},{"title01":"The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia","title02":"The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 26. doi: 10.1111\/bjh.18613. Online ahead of print.","author":"Frisch A, Rowe JM, Ofran Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36572392"},{"title01":"NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1\/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition","title02":"NOTCH1<\/i> mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1\/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 27. doi: 10.1111\/bjh.18609. Online ahead of print.","author":"Carrillo-Tornel S, Chen-Liang TH, Zurdo M, Puiggros A, G\u00f3mez-Llon\u00edn A, Garc\u00eda-Malo MD, Cuenca-Zamora EJ, Ortu\u00f1o FJ, L\u00f3pez AMH, Espinet B, Jerez A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36573331"},{"title01":"Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study","title02":"Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 18. doi: 10.1111\/bjh.18618. Online ahead of print.","author":"Singh C, Yanamandra U, Karunakaran P, Jindal N, Kumar SR, Saini N, Jandial A, Jain A, Das C, Lad D, Prakash G, Khadwal A, Naseem S, Das R, Varma N, Varma S, Malhotra P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36529704"},{"title01":"CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance","title02":"CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 19. doi: 10.1111\/bjh.18607. Online ahead of print.","author":"Jonart LM, Ostergaard J, Brooks A, Fitzpatrick G, Chen L, Gordon PM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36535585"},{"title01":"SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia","title02":"SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 20. doi: 10.1111\/bjh.18606. Online ahead of print.","author":"Tiacci E, Mancini A, Marchetti M, D'Elia GM, Candoni A, Morotti A, Romano A, Gozzetti A, Broccoli A, De Carolis L, Bruna R, Tisi MC, Selleri C, Capponi M, Vallisa D, Cattaneo C, Della Porta MG, Busca A, Falini B, Massaia M, Bert\u00f9 L, Pulsoni A, Rivela P, Corradini P, Passamonti F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36541031"},{"title01":"Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML","title02":"Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 21. doi: 10.1111\/bjh.18622. Online ahead of print.","author":"Scaradavou A, Boelens JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36544239"},{"title01":"SARS-CoV-2 vaccination in CLL: how often is enough?","title02":"SARS-CoV-2 vaccination in CLL: how often is enough?","journal":"Blood","issue":"2022 Dec 22;140(25):2655-2657.","author":"Mellinghoff SC, Cornely OA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548017"},{"title01":"It’s a BRAF new world for hairy cell leukemia","title02":"It’s a BRAF new world for hairy cell leukemia","journal":"Blood","issue":"2022 Dec 22;140(25):2649-2650.","author":"Dearden C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548021"},{"title01":"How I Prevent and Treat Central Nervous System Disease in Adults with Acute Lymphoblastic Leukemia","title02":"How I Prevent and Treat Central Nervous System Disease in Adults with Acute Lymphoblastic Leukemia","journal":"Blood","issue":"Blood. 2022 Dec 22:blood.2022017035. doi: 10.1182\/blood.2022017035. Online ahead of print.","author":"Kopmar NE, Cassaday RD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548957"},{"title01":"Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets","title02":"Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets","journal":"Blood","issue":"Blood. 2022 Dec 22:blood.2022018092. doi: 10.1182\/blood.2022018092. Online ahead of print.","author":"Mishra SK, Millman SE, Zhang L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548959"},{"title01":"Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells","title02":"Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells","journal":"Blood","issue":"Blood. 2022 Dec 23:blood.2022017795. doi: 10.1182\/blood.2022017795. Online ahead of print.","author":"Rimando JC, Chendamarai E, Rettig MP, Jayasinghe RG, Christopher M, Ritchey JK, Christ S, Kim M, Bonvini E, DiPersio JF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36563336"},{"title01":"HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia","title02":"HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia","journal":"Blood","issue":"Blood. 2022 Dec 28:blood.2022016528. doi: 10.1182\/blood.2022016528. Online ahead of print.","author":"Agrawal-Singh S, Bagri J, Giotopoulos G, Azazi D, Horton SJ, Lopez CK, Anand S, Bach AS, Stedham F, Antrobus R, Houghton JW, Vassiliou GS, Sasca D, Yun H, Whetton AD, Huntly BJP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36577137"},{"title01":"An unexpected partnership targeting FLT3wt AML","title02":"An unexpected partnership targeting FLT3wt<\/i> AML","journal":"Blood","issue":"2022 Dec 15;140(24):2529-2530.","author":"Braun T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36520473"},{"title01":"High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL\/HGBL-DH than DLBCL","title02":"High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL\/HGBL-DH than DLBCL","journal":"Leukemia","issue":"Leukemia. 2022 Dec 13. doi: 10.1038\/s41375-022-01778-9. Online ahead of print.","author":"Li S, Qiu L, Xu J, Lin P, Ok CY, Tang G, McDonnell TJ, James You M, Khanlari M, Miranda RN, Jeffrey Medeiros L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36513804"},{"title01":"Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma","title02":"Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Dec 15. doi: 10.1038\/s41375-022-01772-1. Online ahead of print.","author":"Shingaki S, Koya J, Yuasa M, Saito Y, Tabata M, McClure MB, Ogawa S, Katayama K, Togashi Y, Imoto S, Kogure Y, Kataoka K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36522456"},{"title01":"Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma","title02":"Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Dec 20. doi: 10.1038\/s41375-022-01794-9. Online ahead of print.","author":"Casey M, Segawa K, Law SC, Sabdia MB, Nowlan B, Salik B, Lee C, Winterford C, Pearson S, Madore J, Dougall WC, Gandhi MK, Nakamura K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36539557"},{"title01":"High-risk relapsed or refractory classic Hodgkin lymphoma cure: how to make the impossible possible","title02":"High-risk relapsed or refractory classic Hodgkin lymphoma cure: how to make the impossible possible","journal":"Lancet Haematol","issue":"2023 Jan;10(1):e2-e3.","author":"Gallamini A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36566047"},{"title01":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","title02":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","journal":"J Clin Oncol","issue":"2022 Dec 22:JCO2201725. doi: 10.1200\/JCO.22.01725. Online ahead of print.","author":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548927"},{"title01":"Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children’s Oncology Group Trial ANHL12P1","title02":"Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children’s Oncology Group Trial ANHL12P1","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 19:JCO2200272. doi: 10.1200\/JCO.22.00272. Online ahead of print.","author":"Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, Wu R, Alexander S, Bollard CM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36534942"},{"title01":"Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas","title02":"Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 21:JCO2200826. doi: 10.1200\/JCO.22.00826. Online ahead of print.","author":"Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, K\u00fchn J, Bleul S, Olsen M, Liu CL, Jin MC, Macaulay CW, Neidert N, Volk T, Eisenblaetter M, Rauer S, Heiland DH, Finke J, Duyster J, Wehrle J, Prinz M, Illerhaus G, Reinacher PC, Schorb E, Diehn M, Alizadeh AA, Scherer F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36542815"},{"title01":"Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors","title02":"Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors","journal":"Haematologica","issue":"Haematologica. 2022 Dec 15. doi: 10.3324\/haematol.2022.281420. Online ahead of print.","author":"Gerdtsson AS, Matos Rodrigues J, Eskelund CW, Husby S, Gr\u00f8nb\u00e6k K, R\u00e4ty R, Kolstad A, Geisler C, Porwit A, Jerkeman M, Ek S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519324"},{"title01":"Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma","title02":"Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Dec 15. doi: 10.3324\/haematol.2022.281896. Online ahead of print.","author":"Kn\u00f6rr F, Schellekens KPJ, Schoot RA, Landman-Parker J, Teltschik HM, F\u00f6rster J, Riquelme A, Huitema ADR, Van Eijkelenburg NKA, Beishuizen A, Zwaan CM, Woessmann W, Van der Lugt J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519329"},{"title01":"IELSG40\/CLEO phase II trial of clarithromycin and lenalidomide in relapsed\/refractory extranodal marginal zone lymphoma","title02":"IELSG40\/CLEO phase II trial of clarithromycin and lenalidomide in relapsed\/refractory extranodal marginal zone lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.281963. Online ahead of print.","author":"Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Dom\u00e8nech ED, Tucci A, Mannina D, Merli M, Salar A, Visco C, Esposito F, Bonomini L, Zucca E, Ferreri AJM, Raderer M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546422"},{"title01":"End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim-PET","title02":"End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim-PET","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.282115. Online ahead of print.","author":"Chohan KL, Young JR, Lester S, Moustafa MA, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546451"},{"title01":"Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma","title02":"Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Dec 22. doi: 10.3324\/haematol.2022.281472. Online ahead of print.","author":"Lurain K, Ramaswami R, Marshall V, Castro EMC, Labo N, Miley W, Moore K, Roshan R, Mangusan R, Jaffe ES, Pittaluga S, Wang HW, Roth M, Filie AC, Uldrick TS, Whitby D, Yarchoan R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36546459"},{"title01":"Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020","title02":"Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 13. doi: 10.1111\/bjh.18597. Online ahead of print.","author":"Harmanen M, Hujo M, Sund R, Sorigue M, Khan M, Prusila R, Klaavuniemi T, Kari E, Jantunen E, Sunela K, Rajam\u00e4ki A, Alanne E, Kuitunen H, Sancho JM, Jukkola A, R\u00f6nk\u00e4 A, Kuittinen O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36513500"},{"title01":"Lymphocytes in monkeypox infection mimicking T-cell lymphoma","title02":"Lymphocytes in monkeypox infection mimicking T-cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 16. doi: 10.1111\/bjh.18589. Online ahead of print.","author":"Sanou N, Rozen L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36524940"},{"title01":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","title02":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 21. doi: 10.1111\/bjh.18594. Online ahead of print.","author":"Fiaccadori V, Neven A, Fortpied C, Aurer I, Andre M, Federico M, Counsell N, Phillips EH, Clifton-Hadley L, Barrington SF, Illidge T, Radford J, Raemaekers JMM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36541117"},{"title01":"False CD10 positivity in MALT lymphoma involving kidney","title02":"False CD10 positivity in MALT lymphoma involving kidney","journal":"Blood","issue":"2022 Dec 22;140(25):2760.","author":"Kim DH, Thakral B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548012"},{"title01":"Pola-R-CHP for DLBCL: cost-effective at first glance","title02":"Pola-R-CHP for DLBCL: cost-effective at first glance","journal":"Blood","issue":"2022 Dec 22;140(25):2654-2655.","author":"Scheffer Cliff ER, Pandya A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548016"},{"title01":"Novel insights into Hodgkin lymphoma biology by single cell analysis","title02":"Novel insights into Hodgkin lymphoma biology by single cell analysis","journal":"Blood","issue":"Blood. 2022 Dec 22:blood.2022017147. doi: 10.1182\/blood.2022017147. Online ahead of print.","author":"Aoki T, Steidl C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36548960"},{"title01":"Nivolumab, Brentuximab Vedotin, +\/- Bendamustine For R\/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults","title02":"Nivolumab, Brentuximab Vedotin, +\/- Bendamustine For R\/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults","journal":"Blood","issue":"Blood. 2022 Dec 23:blood.2022017118. doi: 10.1182\/blood.2022017118. Online ahead of print.","author":"Harker-Murray P, Mauz-K\u00f6rholz C, Leblanc TM, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano JM, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36564047"},{"title01":"Diffuse large B-cell lymphoma of the testis","title02":"Diffuse large B-cell lymphoma of the testis","journal":"Blood","issue":"2022 Dec 15;140(24):2645.","author":"Falini B, Lazzi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36520471"},{"title01":"Pediatric large B-cell lymphoma with 11q aberration","title02":"Pediatric large B-cell lymphoma with 11q aberration","journal":"Blood","issue":"2022 Dec 15;140(24):2644.","author":"Falini B, Lazzi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36520472"},{"title01":"Post-CAR relapse in DLBCL: a fork in the road","title02":"Post-CAR relapse in DLBCL: a fork in the road","journal":"Blood","issue":"2022 Dec 15;140(24):2527-2529.","author":"Abramson JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36520475"},{"title01":"Core biopsy for lymphoma diagnosis? A needling prospect","title02":"Core biopsy for lymphoma diagnosis? A needling prospect","journal":"Blood","issue":"2022 Dec 15;140(24):2525-2527.","author":"Jaffe ES, Cook JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36520478"},{"title01":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","title02":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","journal":"N Engl J Med","issue":"2022 Dec 13. doi: 10.1056\/NEJMoa2211582. Online ahead of print.","author":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36511784"},{"title01":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","title02":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","journal":"Leukemia","issue":"Leukemia. 2022 Dec 22. doi: 10.1038\/s41375-022-01798-5. Online ahead of print.","author":"Anderson NR, Sheth V, Li H, Harris MW, Qiu S, Crossman DK, Kumar H, Agarwal P, Nagasawa T, Paterson AJ, Welner RS, Bhatia R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36550214"},{"title01":"Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial","title02":"Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial","journal":"Leukemia","issue":"Leukemia. 2022 Dec 22. doi: 10.1038\/s41375-022-01799-4. Online ahead of print.","author":"Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, Bashton M, Enshaei A, Russell LJ, Kingsbury Z, Peden JF, Barretta E, Murray J, Gibson J, Hinchliffe AC, Bain R, Vora A, Bentley DR, Ross MT, Moorman AV, Harrison CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36550215"},{"title01":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY","title02":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY","journal":"Leukemia","issue":"Leukemia. 2022 Dec 24. doi: 10.1038\/s41375-022-01802-y. Online ahead of print.","author":"Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodr\u00edguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylh\u00e4 C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larr\u00e1yoz MJ, Calasanz MJ, F\u00e9s\u00fcs V, M\u00e1trai Z, B\u00f6d\u00f6r C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Taz\u00f3n-Vega B, Baran-Marszak F, Oscier D, N'Guyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hern\u00e1ndez-S\u00e1nchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36566271"},{"title01":"Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia","title02":"Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Dec 26. doi: 10.1038\/s41375-022-01801-z. Online ahead of print.","author":"Rastogi N, Gonzalez JBM, Srivastava VK, Alanazi B, Alanazi RN, Hughes OM, O'Neill NS, Gilkes AF, Ashley N, Deshpande S, Andrews R, Mead A, Rodrigues NP, Knapper S, Darley RL, Tonks A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36572750"},{"title01":"Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children","title02":"Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children","journal":"Leukemia","issue":"Leukemia. 2022 Dec 26. doi: 10.1038\/s41375-022-01796-7. Online ahead of print.","author":"Stratmann S, Vesterlund M, Umer HM, Eshtad S, Skaftason A, Herlin MK, Sundstr\u00f6m C, Eriksson A, H\u00f6glund M, Palle J, Abrahamsson J, Jahnukainen K, Munthe-Kaas MC, Zeller B, Tamm KP, Lindskog C, Cavelier L, Lehti\u00f6 J, Holmfeldt L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36572751"},{"title01":"A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9\/Meis1-dependent AML","title02":"A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9\/Meis1-dependent AML","journal":"Leukemia","issue":"Leukemia. 2022 Dec 14. doi: 10.1038\/s41375-022-01775-y. Online ahead of print.","author":"Lieske A, Agyeman-Duah E, Selich A, D\u00f6rpmund N, Talbot SR, Schambach A, Maetzig T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36517672"},{"title01":"Dual inhibition of CHK1\/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia","title02":"Dual inhibition of CHK1\/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Dec 16. doi: 10.1038\/s41375-022-01795-8. Online ahead of print.","author":"Jiang K, Li X, Wang C, Hu X, Wang P, Tong L, Tu Y, Chen B, Jin T, Wang T, Wang H, Han Y, Gui R, Yang J, Liu T, Li J, Zhou Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36526736"},{"title01":"COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","title02":"COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","journal":"Leukemia","issue":"Leukemia. 2022 Dec 17:1-4. doi: 10.1038\/s41375-022-01787-8. Online ahead of print.","author":"Milojkovic D, Reynolds CJ, Sandoval DM, Pieper FP, Liu S, Pade C, Gibbons JM, McKnight \u00c1, Loaiza S, Palanicawander R, Innes AJ, Claudiani S, Apperley JF, Altmann DM, Boyton RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36528708"},{"title01":"GVHD prediction based on the microbiome","title02":"GVHD prediction based on the microbiome","journal":"Blood","issue":"2022 Dec 1;140(22):2313-2314.","author":"H\u00e4cker G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36454594"},{"title01":"GVHD prevention by personalized nutrition","title02":"GVHD prevention by personalized nutrition","journal":"Blood","issue":"2022 Nov 24;140(21):2190-2192.","author":"Stein-Thoeringer CK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36422858"},{"title01":"Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment","title02":"Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment","journal":"Leukemia","issue":"Leukemia. 2022 Dec 2. doi: 10.1038\/s41375-022-01761-4. Online ahead of print.","author":"Wang X, Cooper S, Broxmeyer HE, Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36460765"},{"title01":"The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia","title02":"The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Nov 26. doi: 10.1038\/s41375-022-01765-0. Online ahead of print.","author":"Hu H, Saha N, Yang Y, Ahmad E, Lachowski L, Shrestha U, Premkumar V, Ropa J, Chen L, Teahan B, Grigsby S, Marschalek R, Nikolovska-Coleska Z, Muntean AG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435883"},{"title01":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","title02":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 6:S2352-3026(22)00330-1. doi: 10.1016\/S2352-3026(22)00330-1. Online ahead of print.","author":"Polverelli N, Hern\u00e1ndez-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kr\u00f6ger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36493799"},{"title01":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions","title02":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions","journal":"Lancet Haematol","issue":"2022 Dec;9(12):e919-e929.","author":"Chang YJ, Pei XY, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36455607"},{"title01":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","title02":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 5:JCO2201780. doi: 10.1200\/JCO.22.01780. Online ahead of print.","author":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, H\u00fcbel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, D\u00fcrig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Dreyling M; European Mantle Cell Lymphoma Network.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36469833"},{"title01":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/ myelodysplastic syndromes after a first transplantation","title02":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/ myelodysplastic syndromes after a first transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Dec 7. doi: 10.3324\/haematol.2022.281877. Online ahead of print.","author":"Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, Nagler A, Shimoni A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36475520"},{"title01":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition","title02":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.280922. Online ahead of print.","author":"B\u00fctow M, Testaquadra FJ, Baumeister J, Mai\u00e9 T, Chatain N, Jaquet T, Tillmann S, Crysandt M, Costa IG, Br\u00fcmmendorf TH, Schemionek M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453102"},{"title01":"Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?","title02":"Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 7. doi: 10.1111\/bjh.18591. Online ahead of print.","author":"Spyridonidis A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36477621"},{"title01":"The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation","title02":"The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 4. doi: 10.1111\/bjh.18585. Online ahead of print.","author":"Luo XY, Kong Y, Lv M, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Tang FF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36464324"},{"title01":"Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation","title02":"Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 5. doi: 10.1111\/bjh.18574. Online ahead of print.","author":"Hino A, Fukushima K, Kusakabe S, Ueda T, Sudo T, Fujita J, Motooka D, Takeda AK, Shinozaki NO, Watanabe S, Yokota T, Shibayama H, Nakamura S, Hosen N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36468273"},{"title01":"Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy","title02":"Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy","journal":"Blood","issue":"Blood. 2022 Dec 9:blood.2022018602. doi: 10.1182\/blood.2022018602. Online ahead of print.","author":"Schnegg-Kaufmann AS, Thoms JAI, Bhuyan GS, Hampton H, Vaughan L, Rutherford KD, Kakadia PM, Lee HM, Johansson EM, Failes TW, Arndt GM, Koval J, Lindeman R, Warburton P, Rodriguez-Meira A, Mead AJ, Unnikrishnan A, Davidson S, Polizzotto M, Hertzberg M, Papaemmanuil E, Bohlander SK, Faridani O, Jolly CJ, Zanini F, Pimanda JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36493342"},{"title01":"Metabolomic profile in patients with primary warm autoimmune haemolytic anaemia","title02":"Metabolomic profile in patients with primary warm autoimmune haemolytic anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 9. doi: 10.1111\/bjh.18584. Online ahead of print.","author":"Rabelo IB, Chiba AK, Moritz E, D'Amora P, Silva IDCG, Rodrigues CA, Barros MMO, Bordin JO.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36484101"},{"title01":"Peripheral agglutination and hemolytic anemia following minor ABO-mismatch hematopoietic progenitor cell transplantation","title02":"Peripheral agglutination and hemolytic anemia following minor ABO-mismatch hematopoietic progenitor cell transplantation","journal":"Blood","issue":"2022 Dec 1;140(22):2412.","author":"Sullivan JC, Comenzo R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36454591"},{"title01":"Diffuse Myocardial Fibrosis Occurs in Young Patients with Sickle Cell Anemia Despite Early Disease Modifying Therapy","title02":"Diffuse Myocardial Fibrosis Occurs in Young Patients with Sickle Cell Anemia Despite Early Disease Modifying Therapy","journal":"Blood","issue":"Blood. 2022 Nov 28:blood.2022018209. doi: 10.1182\/blood.2022018209. Online ahead of print.","author":"Morin C, Sharma A, Selukar S, Beasley G, Merlocco A, Goode C, Rai P, Towbin JA, Hankins JS, Johnson JN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36441963"},{"title01":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study","title02":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 5. doi: 10.1111\/bjh.18582. Online ahead of print.","author":"Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, Tomiyama Y; R788-1301 Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36470677"},{"title01":"Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia","title02":"Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 28. doi: 10.1111\/bjh.18578. Online ahead of print.","author":"Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36442510"},{"title01":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","title02":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 5:JCO2201780. doi: 10.1200\/JCO.22.01780. Online ahead of print.","author":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, H\u00fcbel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, D\u00fcrig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Dreyling M; European Mantle Cell Lymphoma Network.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36469833"},{"title01":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma","title02":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Dec 7. doi: 10.3324\/haematol.2022.282031. Online ahead of print.","author":"Liu Y, Yan F, Jiang VC, Li Y, Che Y, McIntosh J, Jordan A, Hou I, Nie L, Jin J, Wang W, Lee HH, Yao Y, Wang M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36475521"},{"title01":"Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma","title02":"Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281538. Online ahead of print.","author":"Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y, Che Y, Vargas J, Chen Z, Leeming A, Wang W, Yao Y, Wang M, Jiang VC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420799"},{"title01":"Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma","title02":"Landscape of immunoglobulin heavy chain gamma<\/i> gene class switch recombination in patients with adult T-cell leukemia-lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281435. Online ahead of print.","author":"Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420800"},{"title01":"DUSP22 rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma","title02":"DUSP22<\/i> rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.281222. Online ahead of print.","author":"Qiu L, Tang G, Li S, Vega F, Lin P, Wang SA, Wang W, Iyer SP, Malpica L, Miranda RN, Konoplev S, Tang Z, Fang H, Medeiros LJ, Xu J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453104"},{"title01":"ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study","title02":"ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.281442. Online ahead of print.","author":"Sibon D, Bisig B, Bonnet C, Poullot E, Bachy E, Cavalieri D, Fataccioli V, Bregnard C, Drieux F, Bruneau J, Lemonnier F, Dupuy A, Bossard C, Parrens M, Bouabdallah K, Ketterer N, Berthod G, Cairoli A, Damaj G, Tournilhac O, Jais JP, Gaulard P, De Leval L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453105"},{"title01":"DUSP22 rearranged ALK-negative ALCL is a pathogenetically distinct disease but can have variable clinical outcome","title02":"DUSP22<\/i> rearranged ALK-negative ALCL is a pathogenetically distinct disease but can have variable clinical outcome","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.282025. Online ahead of print.","author":"Savage KJ, Slack GW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453106"},{"title01":"Modern real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large-B cell lymphoma with or without double\/triple-hit status in the United States","title02":"Modern real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large-B cell lymphoma with or without double\/triple-hit status in the United States","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.281461. Online ahead of print.","author":"Goyal G, Magnusson T, Wang X, Roose J, Narkhede M, Seymour E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453108"},{"title01":"Targetting glutaminase to starve lymphoma cells","title02":"Targetting glutaminase to starve lymphoma cells","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.282348. Online ahead of print.","author":"Dumontet C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453109"},{"title01":"Methotrexate cytarabine thiotepa rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience","title02":"Methotrexate cytarabine thiotepa rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.282014. Online ahead of print.","author":"Suleman A, Liu J, Hicks LK, Drori AK, Crump M, Kridel R, Prica A, Berinstein N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453110"},{"title01":"Images from the Haematologica Atlas of Hematologic Cytology: anaplastic large cell lymphoma, ALK-negative","title02":"Images from the Haematologica Atlas of Hematologic Cytology: anaplastic large cell lymphoma, ALK-negative","journal":"Haematologica","issue":"2022 Dec 1;107(12):2771.","author":"Invernizzi R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453513"},{"title01":"Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma","title02":"Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 8. doi: 10.1111\/bjh.18598. Online ahead of print.","author":"Cheng CL, Yao CY, Huang PH, Yu CW, Fang WQ, Chuang WH, Wu SJ, Lin YJ, Hung YC, Tsai CH, Yu SC, Chou WC, Tien HF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36480431"},{"title01":"Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era","title02":"Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 9. doi: 10.1111\/bjh.18590. Online ahead of print.","author":"Qualls D, Imber BS, Okwali M, Hamlin PA, Kumar A, Lahoud OB, Matasar MJ, Noy A, Owens C, Zelenetz AD, North VS, Sch\u00f6der H, Dogan A, Salles G, Yahalom J, Falchi L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36484627"},{"title01":"In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103","title02":"In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 9. doi: 10.1111\/bjh.18576. Online ahead of print.","author":"Spriano F, Tarantelli C, Arribas AJ, Gaudio E, Cascione L, Aresu L, Rinaldi A, Zucca E, Rossi D, Stathis A, Murone M, Radtke F, Lehal R, Bertoni F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36484636"},{"title01":"Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative","title02":"Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 1. doi: 10.1111\/bjh.18498. Online ahead of print.","author":"Afify Z, Orjuela-Grimm M, Smith CM, Dalal M, Ford JB, Pillai P, Robles JM, Reddy S, McCormack S, Ehrhardt MJ, Ureda T, Alperstein W, Edington H, Miller TP, Rubinstein JD, Kavanaugh M, Bukowinski AJ, Friehling E, Rivers JM, Chisholm KM, Marks LJ, Mason CC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36454546"},{"title01":"A rare case of primary cutaneous-anaplastic large cell lymphoma (PC-ALCL) localized to the eyelid","title02":"A rare case of primary cutaneous-anaplastic large cell lymphoma (PC-ALCL) localized to the eyelid","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 29. doi: 10.1111\/bjh.18573. Online ahead of print.","author":"Atmaja B, Millard T, Wotherspoon A, Attygalle AD, Cunningham D, Sharma B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36444707"},{"title01":"A N(ew) MYC joins T-cell lymphomagenesis","title02":"A N(ew) MYC joins T-cell lymphomagenesis","journal":"Blood","issue":"2022 Dec 8;140(23):2416-2417.","author":"Farinha P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36480220"},{"title01":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","title02":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","journal":"N Engl J Med","issue":"2022 Dec 15;387(24):2232-2244.","author":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36507686"},{"title01":"Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based m protein assessment","title02":"Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based m protein assessment","journal":"Leukemia","issue":"Leukemia. 2022 Dec 8. doi: 10.1038\/s41375-022-01779-8. Online ahead of print.","author":"Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, Kumar SK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36482129"},{"title01":"Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma","title02":"Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma","journal":"Leukemia","issue":"Leukemia. 2022 Dec 6. doi: 10.1038\/s41375-022-01777-w. Online ahead of print.","author":"Liu J, Lu J, Qiang W, Jia Y, He H, Ye X, Chng WJ, Gale RP, Liang Y, Hou J, Du J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36473979"},{"title01":"How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells","title02":"How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Nov 30:JCO2202114. doi: 10.1200\/JCO.22.02114. Online ahead of print.","author":"van de Donk NWCJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36450104"},{"title01":"In vivo (18) F-fluoride-PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients","title02":"In vivo (18) F-fluoride-PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 8. doi: 10.1111\/bjh.18588. Online ahead of print.","author":"Regelink JC, Zwezerijnen GJC, Groen RJW, Raijmakers PG, Zweegman S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36480438"},{"title01":"Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma","title02":"Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 9. doi: 10.1111\/bjh.18593. Online ahead of print.","author":"Berenson JR, Martinez D, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Swift R, Eades BM, Bujarski S, Regidor B, Kim C, Kim S, Vescio R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36482815"},{"title01":"Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis","title02":"Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 10. doi: 10.1111\/bjh.18568. Online ahead of print.","author":"Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36495317"},{"title01":"VTE prophylaxis in multiple myeloma","title02":"VTE prophylaxis in multiple myeloma","journal":"Blood","issue":"2022 Dec 8;140(23):2413-2414.","author":"Falanga A, Giaccherini C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36480221"},{"title01":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","title02":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Dec 6:S2352-3026(22)00330-1. doi: 10.1016\/S2352-3026(22)00330-1. Online ahead of print.","author":"Polverelli N, Hern\u00e1ndez-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kr\u00f6ger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36493799"},{"title01":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions","title02":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions","journal":"Lancet Haematol","issue":"2022 Dec;9(12):e919-e929.","author":"Chang YJ, Pei XY, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36455607"},{"title01":"Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report","title02":"Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 1:JCO2200461. doi: 10.1200\/JCO.22.00461. Online ahead of print.","author":"Bhatia S, Dai C, Hageman L, Wu J, Schlichting E, Siler A, Funk E, Hicks J, Lim S, Balas N, Bosworth A, Te HS, Francisco L, Bhatia R, Forman SJ, Wong FL, Arora M, Armenian SH, Weisdorf DJ, Landier W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36455192"},{"title01":"Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I\/II Study","title02":"Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I\/II Study","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 2:JCO2200958. doi: 10.1200\/JCO.22.00958. Online ahead of print.","author":"Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36459673"},{"title01":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","title02":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 5:JCO2201780. doi: 10.1200\/JCO.22.01780. Online ahead of print.","author":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, H\u00fcbel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, D\u00fcrig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Dreyling M; European Mantle Cell Lymphoma Network.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36469833"},{"title01":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/ myelodysplastic syndromes after a first transplantation","title02":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/ myelodysplastic syndromes after a first transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Dec 7. doi: 10.3324\/haematol.2022.281877. Online ahead of print.","author":"Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, Nagler A, Shimoni A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36475520"},{"title01":"CMV-specific T-cells following haploidentical transplants: reshaping a repertoire by half","title02":"CMV-specific T-cells following haploidentical transplants: reshaping a repertoire by half","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.282132. Online ahead of print.","author":"O'Reilly RJ, Molvi Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453111"},{"title01":"Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?","title02":"Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 7. doi: 10.1111\/bjh.18591. Online ahead of print.","author":"Spyridonidis A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36477621"},{"title01":"Don’t forget cord blood in non-remission acute myeloid leukaemia!","title02":"Don’t forget cord blood in non-remission acute myeloid leukaemia!","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 12. doi: 10.1111\/bjh.18604. Online ahead of print.","author":"Castagna L, Patti K, Mul\u00e8 A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36507800"},{"title01":"Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative","title02":"Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 1. doi: 10.1111\/bjh.18498. Online ahead of print.","author":"Afify Z, Orjuela-Grimm M, Smith CM, Dalal M, Ford JB, Pillai P, Robles JM, Reddy S, McCormack S, Ehrhardt MJ, Ureda T, Alperstein W, Edington H, Miller TP, Rubinstein JD, Kavanaugh M, Bukowinski AJ, Friehling E, Rivers JM, Chisholm KM, Marks LJ, Mason CC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36454546"},{"title01":"The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation","title02":"The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 4. doi: 10.1111\/bjh.18585. Online ahead of print.","author":"Luo XY, Kong Y, Lv M, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Tang FF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36464324"},{"title01":"Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation","title02":"Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 5. doi: 10.1111\/bjh.18574. Online ahead of print.","author":"Hino A, Fukushima K, Kusakabe S, Ueda T, Sudo T, Fujita J, Motooka D, Takeda AK, Shinozaki NO, Watanabe S, Yokota T, Shibayama H, Nakamura S, Hosen N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36468273"},{"title01":"S100A9 up-regulated by IFNGR signaling blockade functions as a novel GvHD suppressor without compromising GvL in mice","title02":"S100A9 up-regulated by IFNGR signaling blockade functions as a novel GvHD suppressor without compromising GvL in mice","journal":"Blood","issue":"Blood. 2022 Dec 7:blood.2021012687. doi: 10.1182\/blood.2021012687. Online ahead of print.","author":"Kim S, Lim S, Kim B, Ritchey J, Vij K, Prior J, Marsala L, Stoner A, Gao F, Achilefu S, Cooper ML, DiPersio JF, Choi J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36477272"},{"title01":"What a “harmless” antibiotic can teach us about GVL","title02":"What a “harmless” antibiotic can teach us about GVL","journal":"Blood","issue":"2022 Dec 8;140(23):2420-2422.","author":"Maurer K, Soiffer RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36480222"},{"title01":"Peripheral agglutination and hemolytic anemia following minor ABO-mismatch hematopoietic progenitor cell transplantation","title02":"Peripheral agglutination and hemolytic anemia following minor ABO-mismatch hematopoietic progenitor cell transplantation","journal":"Blood","issue":"2022 Dec 1;140(22):2412.","author":"Sullivan JC, Comenzo R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36454591"},{"title01":"Donor NK cells facilitate thymopoiesis in allo-BMT","title02":"Donor NK cells facilitate thymopoiesis in allo-BMT","journal":"Blood","issue":"2022 Dec 1;140(22):2307-2308.","author":"Waller EK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36454592"},{"title01":"Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis","title02":"Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis","journal":"Leukemia","issue":"Leukemia. 2022 Nov 30. doi: 10.1038\/s41375-022-01771-2. Online ahead of print.","author":"Molica S, Giannarelli D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36450894"},{"title01":"Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network","title02":"Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 1:JCO2200437. doi: 10.1200\/JCO.22.00437. Online ahead of print.","author":"Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, L\u00fcbbert M, Sapena R, Nimubona S, Goasguen J, Wattel E, Zini G, Torregrosa Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Navarro R, Patriarca A, Stamatoullas A, G\u00f6tze K, Puttrich M, Mossuto S, Solary E, Gloaguen S, Chevret S, Chermat F, Platzbecker U, Fenaux P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36455187"},{"title01":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/ myelodysplastic syndromes after a first transplantation","title02":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/ myelodysplastic syndromes after a first transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Dec 7. doi: 10.3324\/haematol.2022.281877. Online ahead of print.","author":"Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, Nagler A, Shimoni A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36475520"},{"title01":"Hyperactive CREB subpopulations increase during therapy in paediatric B lineage acute lymphoblastic leukaemia","title02":"Hyperactive CREB subpopulations increase during therapy in paediatric B lineage acute lymphoblastic leukaemia","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281177. Online ahead of print.","author":"Masic D, Fee K, Bell H, Case M, Witherington G, Lansbury S, Ojeda-Garcia J, McDonald D, Schwab C, Van Delft FW, Filby A, Irving JAE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420798"},{"title01":"Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma","title02":"Landscape of immunoglobulin heavy chain gamma<\/i> gene class switch recombination in patients with adult T-cell leukemia-lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281435. Online ahead of print.","author":"Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420800"},{"title01":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition","title02":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition","journal":"Haematologica","issue":"Haematologica. 2022 Dec 1. doi: 10.3324\/haematol.2022.280922. Online ahead of print.","author":"B\u00fctow M, Testaquadra FJ, Baumeister J, Mai\u00e9 T, Chatain N, Jaquet T, Tillmann S, Crysandt M, Costa IG, Br\u00fcmmendorf TH, Schemionek M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453102"},{"title01":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","title02":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","journal":"Haematologica","issue":"2022 Dec 1;107(12):2783-2793.","author":"Saygin C, Cannova J, Stock W, Muffly L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453516"},{"title01":"Measurable residual disease in chronic myeloid leukemia","title02":"Measurable residual disease in chronic myeloid leukemia","journal":"Haematologica","issue":"2022 Dec 1;107(12):2794-2809.","author":"Branford S, Apperley JF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453517"},{"title01":"The present and future of measurable residual disease testing in acute myeloid leukemia","title02":"The present and future of measurable residual disease testing in acute myeloid leukemia","journal":"Haematologica","issue":"2022 Dec 1;107(12):2810-2822.","author":"Blachly JS, Walter RB, Hourigan CS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453518"},{"title01":"Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis","title02":"Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis","journal":"Haematologica","issue":"2022 Dec 1;107(12):2955-2960.","author":"Shimony S, Rozental A, Bewersdorf JP, Goldberg AD, Stein EM, Grimshaw AA, Stone RM, DeAngelo DJ, Wolach O, Stahl M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453519"},{"title01":"Structure-function analysis of the role of megakaryoblastic leukemia 1 in megakaryocyte polyploidization","title02":"Structure-function analysis of the role of megakaryoblastic leukemia 1 in megakaryocyte polyploidization","journal":"Haematologica","issue":"2022 Dec 1;107(12):2972-2976.","author":"Reed FE, Eskow NM, Min E, Carlino M, Mancuso R, Kwon N, Smith EC, Larsuel ST, Wang L, Scanlon V, Krause DS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36453520"},{"title01":"Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia","title02":"Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 9. doi: 10.1111\/bjh.18602. Online ahead of print.","author":"Sorcini D, De Falco F, Gargaro M, Bozza S, Guarente V, Cardinali V, Stella A, Adamo FM, Silva Barcelos EC, Rompietti C, Dorillo E, Geraci C, Esposito A, Arcaleni R, Capoccia S, Mameli MG, Graziani A, Moretti L, Cipiciani A, Riccardi C, Mencacci A, Fallarino F, Rosati E, Sportoletti P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36484163"},{"title01":"Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia","title02":"Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 9. doi: 10.1111\/bjh.18601. Online ahead of print.","author":"Zheng Y, Weng X, Hu D, He J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36484284"},{"title01":"Don’t forget cord blood in non-remission acute myeloid leukaemia!","title02":"Don’t forget cord blood in non-remission acute myeloid leukaemia!","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 12. doi: 10.1111\/bjh.18604. Online ahead of print.","author":"Castagna L, Patti K, Mul\u00e8 A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36507800"},{"title01":"Successful bridging to cell therapy for relapsed\/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase","title02":"Successful bridging to cell therapy for relapsed\/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Dec 5. doi: 10.1111\/bjh.18595. Online ahead of print.","author":"Goursaud L, Berthon C, Quesnel B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36470305"},{"title01":"Treatment response in acute myeloid leukaemia-Clues in the biopsy core","title02":"Treatment response in acute myeloid leukaemia-Clues in the biopsy core","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 28. doi: 10.1111\/bjh.18579. Online ahead of print.","author":"Aguilar Navarro AG, Tikhonova AN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36441107"},{"title01":"Bundles of Auer rods in mature neutrophils in an acute myeloid leukaemia patient with inv(16)(p13.1q22) CBFB-MYH 11","title02":"Bundles of Auer rods in mature neutrophils in an acute myeloid leukaemia patient with inv(16)(p13.1q22) CBFB-MYH 11","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 28. doi: 10.1111\/bjh.18559. Online ahead of print.","author":"Rakotoarivelo ZH, Lefebvre T, Lamarque M, Harzallah I, Debliquis A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36441114"},{"title01":"Dinner-plate nuclei in hypogranular acute promyelocytic leukemia","title02":"Dinner-plate nuclei in hypogranular acute promyelocytic leukemia","journal":"Blood","issue":"2022 Dec 8;140(23):2519.","author":"Zahid MF, Kainthla R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36480218"},{"title01":"Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy","title02":"Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy","journal":"Blood","issue":"Blood. 2022 Dec 9:blood.2022018602. doi: 10.1182\/blood.2022018602. Online ahead of print.","author":"Schnegg-Kaufmann AS, Thoms JAI, Bhuyan GS, Hampton H, Vaughan L, Rutherford KD, Kakadia PM, Lee HM, Johansson EM, Failes TW, Arndt GM, Koval J, Lindeman R, Warburton P, Rodriguez-Meira A, Mead AJ, Unnikrishnan A, Davidson S, Polizzotto M, Hertzberg M, Papaemmanuil E, Bohlander SK, Faridani O, Jolly CJ, Zanini F, Pimanda JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36493342"},{"title01":"Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia","title02":"Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia","journal":"Blood","issue":"Blood. 2022 Dec 9:blood.2022016678. doi: 10.1182\/blood.2022016678. Online ahead of print.","author":"Przespolewski A, Goldberg AD, Talati C, Fazal S, Vachhani P, Sanikommu SR, Thota S, Waksal JA, Ball BJ, Famulare CA, Stahl M, Baron J, Griffiths EA, Thompson JE, Sweet KL, Wang ES.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36493344"},{"title01":"RUNX1 isoform disequilibrium promotes the development of trisomy 21 associated myeloid leukemia","title02":"RUNX1<\/i> isoform disequilibrium promotes the development of trisomy 21 associated myeloid leukemia","journal":"Blood","issue":"Blood. 2022 Dec 9:blood.2022017619. doi: 10.1182\/blood.2022017619. Online ahead of print.","author":"Gialesaki S, Br\u00e4uer-Hartmann D, Issa H, Bhayadia R, Alejo-Valle O, Verboon L, Schmell AL, Laszig S, Regenyi EM, Schuschel K, Labuhn M, Ng M, Winkler R, Ihling C, Sinz A, Gla\u00df M, H\u00fcttelmaier S, Matzk S, Schmid L, Str\u00fcwe FJ, Kadel SK, Reinhardt D, Yaspo ML, Heckl D, Klusmann JH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36493345"},{"title01":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","title02":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","journal":"Blood","issue":"Blood. 2022 Dec 12:blood.2021011094. doi: 10.1182\/blood.2021011094. Online ahead of print.","author":"Kuusanm\u00e4ki H, Dufva O, V\u00e4h\u00e4-Koskela M, Lepp\u00e4 AM, Huuhtanen J, V\u00e4nttinen IM, Nygren PJ, Klievink J, Bouhlal JOV, P\u00f6l\u00f6nen P, Zhang Q, Adnan Awad S, Mancebo-P\u00e9rez C, Saad J, Miettinen JJ, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Hein\u00e4niemi M, Theilgaard-M\u00f6nch K, Wartiovaara-Kautto U, Ker\u00e4nen MAI, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36508699"},{"title01":"Overlapping features of therapy-related and de novoNPM1-mutated AML","title02":"Overlapping features of therapy-related and de novoNPM1<\/i>-mutated AML","journal":"Blood","issue":"Blood. 2022 Dec 12:blood.2022018108. doi: 10.1182\/blood.2022018108. Online ahead of print.","author":"Othman J, Meggendorfer M, Tiacci E, Thiede C, Schlenk RF, Dillon R, Stasik S, Venanzi A, Bertoli S, Delabesse E, Dumas PY, Pigneux A, Bidet A, Gilkes AF, Thomas I, Voso MT, Rambaldi A, Brunetti L, Perriello VM, Andresen V, Gjertsen BT, Martelli MP, R\u00e9cher C, Serve H, M\u00fcller-Tidow C, Baldus CD, Haferlach T, Russell NH, Falini B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36508705"},{"title01":"Activation of the PP2A-B56\u03b1 heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation","title02":"Activation of the PP2A-B56\u03b1 heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation","journal":"Blood","issue":"Blood. 2022 Dec 1:blood.2022016466. doi: 10.1182\/blood.2022016466. Online ahead of print.","author":"Peris I, Romero-Murillo S, Mart\u00ednez-Balsalobre E, Farrington CC, Arriazu E, Marcotegui N, Jim\u00e9nez-Mu\u00f1oz M, Alburquerque-Prieto C, Torres-L\u00f3pez A, Fresquet VJ, Martinez-Climent JA, Mateos MC, Cayuela ML, Narla G, Odero MD, Vicente C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36455198"},{"title01":"Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia","title02":"Somatic TP53<\/i> mutations are pre-leukemic events in acute lymphoblastic leukemia","journal":"Blood","issue":"Blood. 2022 Nov 30:blood.2022017249. doi: 10.1182\/blood.2022017249. Online ahead of print.","author":"Chitadze G, Stengel A, John-Klaua C, Bruckm\u00fcller J, Trautmann H, Kotrova M, Darzentas F, Kelm M, Pal K, Darzentas N, Bastian L, Kehden B, Wessels W, Str\u00f6h AS, Oberg HH, Altrock PM, Baer C, Meggendorfer M, Haferlach C, Goekbuget N, Baldus CD, Br\u00fcggemann M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36450137"},{"title01":"Bispecific Antibodies in Lymphoma – Another Win for T Cells","title02":"Bispecific Antibodies in Lymphoma – Another Win for T Cells","journal":"N Engl J Med","issue":"2022 Dec 15;387(24):2285-2286.","author":"Bartlett NL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36507659"},{"title01":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","title02":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","journal":"N Engl J Med","issue":"2022 Dec 15;387(24):2220-2231.","author":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wr\u00f3bel T, Offner F, Trn\u011bn\u00fd M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36507690"},{"title01":"Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma","title02":"Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Dec 12. doi: 10.1038\/s41375-022-01776-x. Online ahead of print.","author":"Sureda-G\u00f3mez M, Balsas P, Rodr\u00edguez ML, Nadeu F, De Bol\u00f2s A, Eguileor \u00c1, Kulis M, Castellano G, L\u00f3pez C, Gin\u00e9 E, Demajo S, Jares P, Mart\u00edn-Subero JI, Be\u00e0 S, Campo E, Amador V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36509891"},{"title01":"Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma","title02":"Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Dec 1. doi: 10.1038\/s41375-022-01774-z. Online ahead of print.","author":"Wei W, Song Z, Chiba M, Wu W, Jeong S, Zhang JP, Kadin ME, Nakagawa M, Yang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36456744"},{"title01":"A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas","title02":"A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas","journal":"Leukemia","issue":"Leukemia. 2022 Dec 2. doi: 10.1038\/s41375-022-01764-1. Online ahead of print.","author":"Falini B, Martino G, Lazzi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36460764"},{"title01":"Sustained activation of non-canonical NF-\u03baB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL","title02":"Sustained activation of non-canonical NF-\u03baB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL","journal":"Leukemia","issue":"Leukemia. 2022 Nov 30. doi: 10.1038\/s41375-022-01769-w. Online ahead of print.","author":"Lim SK, Peng CC, Low S, Vijay V, Budiman A, Phang BH, Lim JQ, Jeyasekharan AD, Lim ST, Ong CK, Tan SM, Li Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36446947"},{"title01":"The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium","title02":"The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium","journal":"J Clin Oncol","issue":"2022 Dec 10:JCO2202473. doi: 10.1200\/JCO.22.02473. Online ahead of print.","author":"Rodday AM, Parsons SK, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link BK, Mou E, Savage KJ, Zinzani PL, Maurer M, Evens AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36495588"},{"title01":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","title02":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 12:JCO2202355. doi: 10.1200\/JCO.22.02355. Online ahead of print.","author":"Br\u00f6ckelmann PJ, B\u00fchnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36508302"},{"title01":"Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma","title02":"Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Dec 12:JCO2201848. doi: 10.1200\/JCO.22.01848. Online ahead of print.","author":"Nastoupil LJ, Bartlett NL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36508700"},{"title01":"Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms","title02":"Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms","journal":"Leukemia","issue":"Leukemia. 2022 Dec 12. doi: 10.1038\/s41375-022-01786-9. Online ahead of print.","author":"Walti CS, Halpern AB, Xie H, Kiem ES, Chung EL, Schonhoff KG, Huebner EM, Delaney C, Liu C, Pergam SA, Cheng GS, Kimball LE, Leisenring WM, Boeckh M, Walter RB, Hill JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36509892"},{"title01":"A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients","title02":"A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients","journal":"Leukemia","issue":"Leukemia. 2022 Dec 12. doi: 10.1038\/s41375-022-01785-w. Online ahead of print.","author":"Massacci G, Venafra V, Latini S, Bica V, Pugliese GM, Graziosi S, Klingelhuber F, Krahmer N, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36509894"},{"title01":"Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: “High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance”","title02":"Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: “High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance”","journal":"Leukemia","issue":"Leukemia. 2022 Nov 24. doi: 10.1038\/s41375-022-01763-2. Online ahead of print.","author":"Vangala DB, Nilius-Eliliwi V, Gerding WM, Schroers R, Nguyen HP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36434063"},{"title01":"Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms","title02":"Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms","journal":"Leukemia","issue":"Leukemia. 2022 Nov 25. doi: 10.1038\/s41375-022-01745-4. Online ahead of print.","author":"Paras G, Othus M, Schonhoff K, Shaw C, Sorror M, Halpern AB, Appelbaum J, Hendrie P, Walter RB, Estey EH, Percival MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36434064"},{"title01":"The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia","title02":"The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Nov 26. doi: 10.1038\/s41375-022-01765-0. Online ahead of print.","author":"Hu H, Saha N, Yang Y, Ahmad E, Lachowski L, Shrestha U, Premkumar V, Ropa J, Chen L, Teahan B, Grigsby S, Marschalek R, Nikolovska-Coleska Z, Muntean AG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435883"},{"title01":"Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","title02":"Prognostic implications of mono-hit and multi-hit TP53<\/i> alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","journal":"Leukemia","issue":"Leukemia. 2022 Nov 27. doi: 10.1038\/s41375-022-01766-z. Online ahead of print.","author":"Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36437356"},{"title01":"Should we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors?","title02":"Should we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors?","journal":"Leukemia","issue":"Leukemia. 2022 Nov 16. doi: 10.1038\/s41375-022-01760-5. Online ahead of print.","author":"Calvo X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36385279"},{"title01":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia","title02":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Nov 18. doi: 10.1038\/s41375-022-01755-2. Online ahead of print.","author":"Ling VY, Straube J, Godfrey W, Haldar R, Janardhanan Y, Cooper L, Bruedigam C, Cooper E, Tavakoli Shirazi P, Jacquelin S, Tey SK, Baell J, Huang F, Jin J, Zhao Y, Bullinger L, Bywater MJ, Lane SW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36400926"},{"title01":"Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)","title02":"Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA<\/i> activation due to insulator disruption in acute myeloid leukemia (AML)","journal":"Leukemia","issue":"Leukemia. 2022 Nov 21. doi: 10.1038\/s41375-022-01751-6. Online ahead of print.","author":"Steinh\u00e4user S, Silva P, Lenk L, Beder T, Hartmann A, H\u00e4nzelmann S, Fransecky L, Neumann M, Bastian L, Lipinski S, Richter K, Bultmann M, H\u00fcbner E, Xia S, R\u00f6llig C, Vogiatzi F, Schewe DM, Yumiceba V, Schultz K, Spielmann M, Baldus CD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36411356"},{"title01":"Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia","title02":"Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1<\/i>-fusion-positive acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Nov 11. doi: 10.1038\/s41375-022-01752-5. Online ahead of print.","author":"Mandell JD, Fisk JN, Cyrenne E, Xu ML, Cannataro VL, Townsend JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36369483"},{"title01":"VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia","title02":"VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Nov 14. doi: 10.1038\/s41375-022-01758-z. Online ahead of print.","author":"Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36376377"},{"title01":"Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO","title02":"Gilteritinib activity in refractory or relapsed FLT3<\/i>-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO","journal":"Leukemia","issue":"Leukemia. 2022 Nov 14. doi: 10.1038\/s41375-022-01742-7. Online ahead of print.","author":"Dumas PY, Raffoux E, B\u00e9rard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Gui\u00e8ze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, B\u00e9n\u00e9 MC, Mineur A, Pigneux A, Dombret H, R\u00e9cher C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36376378"},{"title01":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","title02":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A<\/i>-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","journal":"Leukemia","issue":"Leukemia. 2022 Nov 15. doi: 10.1038\/s41375-022-01746-3. Online ahead of print.","author":"Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36380143"},{"title01":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","title02":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Nov 16:S2352-3026(22)00319-2. doi: 10.1016\/S2352-3026(22)00319-2. Online ahead of print.","author":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36402146"},{"title01":"Towards chemotherapy-free treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia","title02":"Towards chemotherapy-free treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Nov 16:S2352-3026(22)00351-9. doi: 10.1016\/S2352-3026(22)00351-9. Online ahead of print.","author":"Boer JM, van der Sluis IM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36402147"},{"title01":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","title02":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Nov 9:S2352-3026(22)00292-7. doi: 10.1016\/S2352-3026(22)00292-7. Online ahead of print.","author":"Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, R\u00e9cher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36370742"},{"title01":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","title02":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200\/JCO.22.00510. Online ahead of print.","author":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, \u0160imkovi\u010d M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, \u00d6sterborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36395435"},{"title01":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","title02":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Nov 18:JCO2200642. doi: 10.1200\/JCO.22.00642. Online ahead of print.","author":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M, Buechner J, Pulsipher MA, Myers GD, Stefanski HE, Martin PL, Nemecek E, Peters C, Yanik G, Khaw SL, Davis KL, Krueger J, Balduzzi A, Boissel N, Tiwari R, O'Donovan D, Grupp SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36399695"},{"title01":"Dysfunctional subsets of CD39+ T cells, distinct from PD-1+, driven by leukemic extracellular vesicles in myeloid leukemias","title02":"Dysfunctional subsets of CD39+ T cells, distinct from PD-1+, driven by leukemic extracellular vesicles in myeloid leukemias","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.281713. Online ahead of print.","author":"Swatler J, Lo Tartaro D, Borella R, Brewinska-Olchowik M, Paolini A, Neroni A, Turos-Korgul L, Wiech M, Kozlowska E, Cysewski D, Grabowska-Pyrzewicz W, Wojda U, Basak G, Arg\u00fcello RJ, Cossarizza A, De Biasi S, Piwocka K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384249"},{"title01":"Clinical response to dabrafenib and chemotherapy in clonally-related histiocytosis and acute lymphoblastic leukemia","title02":"Clinical response to dabrafenib and chemotherapy in clonally-related histiocytosis and acute lymphoblastic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.281926. Online ahead of print.","author":"Hubert G, Bittencourt H, Laverdi\u00e8re C, Teira P, Cellot S, Langlois S, Rouette A, Sontag T, Sinnett D, Dal-Soglio D, Turpin S, Tran TH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384252"},{"title01":"Disrupting autophagy in FLT3-mutant AML","title02":"Disrupting autophagy in FLT3-mutant AML","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.282054. Online ahead of print.","author":"Grant S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384254"},{"title01":"Hyperactive CREB subpopulations increase during therapy in paediatric B lineage acute lymphoblastic leukaemia","title02":"Hyperactive CREB subpopulations increase during therapy in paediatric B lineage acute lymphoblastic leukaemia","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281177. Online ahead of print.","author":"Masic D, Fee K, Bell H, Case M, Witherington G, Lansbury S, Ojeda-Garcia J, McDonald D, Schwab C, Van Delft FW, Filby A, Irving JAE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420798"},{"title01":"Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma","title02":"Landscape of immunoglobulin heavy chain gamma<\/i> gene class switch recombination in patients with adult T-cell leukemia-lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281435. Online ahead of print.","author":"Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420800"},{"title01":"A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial","title02":"A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 22. doi: 10.1111\/bjh.18560. Online ahead of print.","author":"Mussai F, De Santo C, Cheng P, Thomas IF, Ariti C, Upton L, Scarpa U, Stavrou V, Sydenham M, Burnett AK, Knapper SK, Mehta P, McMullin MF, Copland M, Russell NH, Dennis M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36413792"},{"title01":"Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles","title02":"Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 10. doi: 10.1111\/bjh.18513. Online ahead of print.","author":"Treaba DO, Bonal DM, Chorzalska A, Castillo-Martin M, Oakes A, Pardo M, Petersen M, Schorl C, Hopkins K, Melcher D, Zhao TC, Liang O, So EY, Reagan J, Olszewski AJ, Butera J, Anthony DC, Rintels P, Quesenberry P, Dubielecka PM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354085"},{"title01":"Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia","title02":"Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 10. doi: 10.1111\/bjh.18558. Online ahead of print.","author":"Paul SR, Rosing DR, Haigney MC, Peer CJ, Figg WD, Wiestner A, Sun C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36366824"},{"title01":"Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues","title02":"Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 10. doi: 10.1111\/bjh.18557. Online ahead of print.","author":"Meszaros N, Lind K, Sehlke R, Vilagos B, Krall N, Vladimer GI, Sill H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36366863"},{"title01":"Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia","title02":"Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 11. doi: 10.1111\/bjh.18527. Online ahead of print.","author":"Zhang T, Liu X, Fei H, Zhang L, Ma R, Shen Y, Pang A, Yang D, Chen X, Zhang R, Wei J, He Y, Jiang E, Han M, Feng S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36367209"},{"title01":"Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma","title02":"Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 14. doi: 10.1111\/bjh.18565. Online ahead of print.","author":"Dong Q, Wang Y, Xiu Y, Sakr H, Burnworth B, Xu D, O'Brien T, Burke J, Hu S, Zeng G, Zhao C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36375473"},{"title01":"FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation","title02":"FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation","journal":"Blood","issue":"Blood. 2022 Nov 17:blood.2022016889. doi: 10.1182\/blood.2022016889. Online ahead of print.","author":"Li Y, Yang W, Patel RM, Casey EB, Denby ED, Mendoza-Castrejon J, Rodriguez-Lopez P, Magee JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36395068"},{"title01":"AML gets upSET when its dietary needs are unMet","title02":"AML gets upSET when its dietary needs are unMet","journal":"Blood","issue":"2022 Nov 10;140(19):2003-2004.","author":"Gallipoli P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36355468"},{"title01":"-----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts","title02":"-----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts","journal":"Blood","issue":"Blood. 2022 Nov 14:blood.2022016934. doi: 10.1182\/blood.2022016934. Online ahead of print.","author":"Zhang D, Harris HM, Chen J, Judy JT, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing ER, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Piroozia M, Sk\u00e5nland SS, Gaglione EM, Mhibik M, Underbayev C, Ahn I, Sun C, Herman SEM, Noviski MA, Wiestner A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36375120"},{"title01":"Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia","title02":"Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia","journal":"Blood","issue":"Blood. 2022 Nov 15:blood.2022018051. doi: 10.1182\/blood.2022018051. Online ahead of print.","author":"Dores GM, Linet MS, Curtis RE, Morton LM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36379026"},{"title01":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","title02":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Nov 17:S2352-3026(22)00318-0. doi: 10.1016\/S2352-3026(22)00318-0. Online ahead of print.","author":"Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36403579"},{"title01":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","title02":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200\/JCO.22.00510. Online ahead of print.","author":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, \u0160imkovi\u010d M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, \u00d6sterborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36395435"},{"title01":"Prevention and management of secondary central nervous system lymphoma","title02":"Prevention and management of secondary central nervous system lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.281457. Online ahead of print.","author":"Bobillo S, Khwaja J, Ferreri AJ, Cwynarski K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384246"},{"title01":"Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)","title02":"Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.281407. Online ahead of print.","author":"Tucci A, Merli F, Fabbri A, Marcheselli L, Pagani C, Puccini B, Marino D, Zanni M, Pennese E, Flenghi L, Arcari A, Botto B, Celli M, Mammi C, Re A, Campostrini G, Tafuri A, Zilioli VR, Cencini E, Sartori R, Bottelli C, Merli M, Petrucci L, Gini G, Balzarotti M, Cavallo F, Musuraca G, Luminari S, Rossi G, Spina M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384247"},{"title01":"Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm","title02":"Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.281724. Online ahead of print.","author":"Liu Y, Derkach A, Lewis N, Zhu M, Zhang Y, Arcila M, Salles G, Dogan A, Xiao W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384248"},{"title01":"Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response","title02":"Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.281954. Online ahead of print.","author":"Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384251"},{"title01":"Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma","title02":"Landscape of immunoglobulin heavy chain gamma<\/i> gene class switch recombination in patients with adult T-cell leukemia-lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Nov 24. doi: 10.3324\/haematol.2022.281435. Online ahead of print.","author":"Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36420800"},{"title01":"A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race","title02":"A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 18. doi: 10.1111\/bjh.18564. Online ahead of print.","author":"Shah H, Jang H, Kim S, Halwani AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36400571"},{"title01":"Management of secondary central nervous system lymphoma","title02":"Management of secondary central nervous system lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 21. doi: 10.1111\/bjh.18539. Online ahead of print.","author":"Cwynarski K, Cummin T, Osborne W, Lewis J, Chaganti S, Smith J, Linton K, Greaves P, McKay P, Fox CP; British Society for Haematology (BSH) Committee.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36408800"},{"title01":"Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma","title02":"Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 14. doi: 10.1111\/bjh.18565. Online ahead of print.","author":"Dong Q, Wang Y, Xiu Y, Sakr H, Burnworth B, Xu D, O'Brien T, Burke J, Hu S, Zeng G, Zhao C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36375473"},{"title01":"How I treat Elderly Patients with DLBCL in the frontline setting","title02":"How I treat Elderly Patients with DLBCL in the frontline setting","journal":"Blood","issue":"Blood. 2022 Nov 22:blood.2020008239. doi: 10.1182\/blood.2020008239. Online ahead of print.","author":"Lugtenburg PJ, Mutsaers PGNJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36413153"},{"title01":"BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1","title02":"BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1","journal":"Blood","issue":"Blood. 2022 Nov 14:blood.2022016943. doi: 10.1182\/blood.2022016943. Online ahead of print.","author":"Delage L, Lambert M, Bardel E, Kundlacz C, Chartoire D, Conchon A, Peugnet AL, Gorka L, Auberger P, Jacquel A, Soussain C, Destaing O, Delecluse HJ, Delecluse S, Merabet S, Traverse-Glehen A, Salles GA, Bachy E, Billaud M, Ghesquieres H, Genestier L, Rouault JP, Sujobert P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36375119"},{"title01":"Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","title02":"Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Nov 22:JCO2102734. doi: 10.1200\/JCO.21.02734. Online ahead of print.","author":"Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36413710"},{"title01":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","title02":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","journal":"Blood","issue":"Blood. 2022 Nov 14:blood.2022017863. doi: 10.1182\/blood.2022017863. Online ahead of print.","author":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mah\u00e9o S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H, Corre J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36375118"},{"title01":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","title02":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Nov 17:S2352-3026(22)00318-0. doi: 10.1016\/S2352-3026(22)00318-0. Online ahead of print.","author":"Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36403579"},{"title01":"Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors","title02":"Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 16. doi: 10.1111\/bjh.18561. Online ahead of print.","author":"Merli P, Crivello P, Strocchio L, Pinto RM, Algeri M, Del Bufalo F, Pagliara D, Becilli M, Carta R, Gaspari S, Galaverna F, Quagliarella F, Boz G, Catanoso ML, Boccieri E, Troiano M, Fleischhauer K, Andreani M, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36385618"},{"title01":"Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia","title02":"Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 11. doi: 10.1111\/bjh.18527. Online ahead of print.","author":"Zhang T, Liu X, Fei H, Zhang L, Ma R, Shen Y, Pang A, Yang D, Chen X, Zhang R, Wei J, He Y, Jiang E, Han M, Feng S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36367209"},{"title01":"A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study","title02":"A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 12. doi: 10.1111\/bjh.18550. Online ahead of print.","author":"Choi Y, Choi EJ, Park HS, Lee JH, Lee JH, Lee YS, Kang YA, Jeon M, Woo JM, Kang H, Baek S, Kim SM, Bong CE, Lee KH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36370064"},{"title01":"Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation","title02":"Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 16. doi: 10.1111\/bjh.18562. Online ahead of print.","author":"Bankova AK, Pasin C, Huang A, Cicin-Sain C, Epp S, Audige A, Mueller NJ, Nilsson J, Vilinovszki O, Nair G, Wolfensberger N, Hockl P, Schanz U, Trkola A, Kouyos R, Hasse B, Zinkernagel AS, Manz MG, Abela IA, M\u00fcller AMS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36382698"},{"title01":"How we diagnose and treat acute graft-versus-host disease after solid organ transplantation","title02":"How we diagnose and treat acute graft-versus-host disease after solid organ transplantation","journal":"Blood","issue":"Blood. 2022 Nov 17:blood.2022015954. doi: 10.1182\/blood.2022015954. Online ahead of print.","author":"Cooper JP, Abkowitz JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36395067"},{"title01":"A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","title02":"A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","journal":"Blood","issue":"Blood. 2022 Nov 18:blood.2021015111. doi: 10.1182\/blood.2021015111. Online ahead of print.","author":"Ponce DM, Alousi AM, Nakamura R, Slingerland J, Calafiore M, Sandhu KS, Barker JN, Devlin SM, Shia J, Giralt SA, Perales MA, Moore GF, Fatmi S, Soto C, Gomes AL, Giardina P, Marcello LT, Yan X, Tang T, Dreyer K, Chen J, Daley WL, Peled JU, van den Brink MRM, Hanash A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36399701"},{"title01":"A Novel RIPK1 Inhibitor Reduces GVHD in Mice via a Non-immunosuppressive Mechanism that Restores Intestinal Homeostasis","title02":"A Novel RIPK1 Inhibitor Reduces GVHD in Mice via a Non-immunosuppressive Mechanism that Restores Intestinal Homeostasis","journal":"Blood","issue":"Blood. 2022 Nov 10:blood.2022017262. doi: 10.1182\/blood.2022017262. Online ahead of print.","author":"Yu X, Ma H, Li B, Ji Y, Du Y, Liu S, Li Z, Hao Y, Tian S, Zhao C, Du Q, Jin Z, Zhu X, Tian Y, Chen X, Sun X, Yang C, Zhu F, Ju J, Zheng Y, Zhang W, Wang J, Yang T, Wang X, Li J, Xu X, Du S, Lu H, Ma F, Zhang H, Zhang Y, Zhang X, Hu S, He S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36356302"},{"title01":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","title02":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Nov 17:S2352-3026(22)00318-0. doi: 10.1016\/S2352-3026(22)00318-0. Online ahead of print.","author":"Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36403579"},{"title01":"Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors","title02":"Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 16. doi: 10.1111\/bjh.18561. Online ahead of print.","author":"Merli P, Crivello P, Strocchio L, Pinto RM, Algeri M, Del Bufalo F, Pagliara D, Becilli M, Carta R, Gaspari S, Galaverna F, Quagliarella F, Boz G, Catanoso ML, Boccieri E, Troiano M, Fleischhauer K, Andreani M, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36385618"},{"title01":"Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia","title02":"Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 11. doi: 10.1111\/bjh.18527. Online ahead of print.","author":"Zhang T, Liu X, Fei H, Zhang L, Ma R, Shen Y, Pang A, Yang D, Chen X, Zhang R, Wei J, He Y, Jiang E, Han M, Feng S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36367209"},{"title01":"A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study","title02":"A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 12. doi: 10.1111\/bjh.18550. Online ahead of print.","author":"Choi Y, Choi EJ, Park HS, Lee JH, Lee JH, Lee YS, Kang YA, Jeon M, Woo JM, Kang H, Baek S, Kim SM, Bong CE, Lee KH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36370064"},{"title01":"Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation","title02":"Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Nov 16. doi: 10.1111\/bjh.18562. Online ahead of print.","author":"Bankova AK, Pasin C, Huang A, Cicin-Sain C, Epp S, Audige A, Mueller NJ, Nilsson J, Vilinovszki O, Nair G, Wolfensberger N, Hockl P, Schanz U, Trkola A, Kouyos R, Hasse B, Zinkernagel AS, Manz MG, Abela IA, M\u00fcller AMS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36382698"},{"title01":"Allogeneic HCT for Ph+ ALL in CR1 with CMR","title02":"Allogeneic HCT for Ph+ ALL in CR1 with CMR","journal":"Blood","issue":"2022 Nov 17;140(20):2181.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36394902"},{"title01":"Animal models of Diamond-Blackfan anemia: updates and challenges","title02":"Animal models of Diamond-Blackfan anemia: updates and challenges","journal":"Haematologica","issue":"Haematologica. 2022 Nov 17. doi: 10.3324\/haematol.2022.282042. Online ahead of print.","author":"Liu YL, Shibuya A, Glader B, Wilkes MC, Barna M, Sakamoto KM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36384250"},{"title01":"Hydroxyurea is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa","title02":"Hydroxyurea is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa","journal":"Blood","issue":"Blood. 2022 Nov 14:blood.2022017051. doi: 10.1182\/blood.2022017051. Online ahead of print.","author":"Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo LMM, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham T, Ware RE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36375125"},{"title01":"Platelet satellitism in immune thrombocytopenic purpura","title02":"Platelet satellitism in immune thrombocytopenic purpura","journal":"Blood","issue":"2022 Nov 10;140(19):2091.","author":"Markewitz RDH, Falk KK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36355464"}]